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Abstract 
 
Chemotherapeutic drugs are widely used for the treatment of cancer but their 
debilitating side effects often lead to alterations in dose regimens and the premature 
cessation of treatment, which ultimately impacts on patient’s survival. Chemotherapy-
induced neuropathy (CIN) is one of the most common side effects of chemotherapeutic 
drugs. CIN results from the damaging action of cytostatic drugs on peripheral nerves. 
Paclitaxel is a commonly prescribed cytostatic known to damage sensory nerves and to 
produce neuropathic pain characterized by mechanical and thermal hypersensitivity. The 
molecular mechanisms underlying the onset of CIN by paclitaxel have been mainly 
investigated at the level of the peripheral nervous system but the effects of paclitaxel at 
the central nervous system level are still understudied. Here we studied the effects of 
the cytostatic paclitaxel at the spinal cord, the first relay site in the transmission of 
nociceptive information from the periphery to the brain. Three studies were included in 
the present thesis which aimed at: i) determining the onset and maintenance of 
nociceptive and aversive behaviors; ii) assessing basal and noxious-evoked activation 
of spinal dorsal horn neurons and iii) studying the descending inhibitory noradrenergic 
modulatory system. 
Adult male Wistar rats were intraperitoneally injected with paclitaxel (Taxol®, 2.0 
mg/kg) or the vehicle solution Dimethyl Sulfoxide (DMSO) or saline on four alternate 
days. Nociceptive and aversive behaviors were assessed by the von Frey and the 
Conditioned Place Aversion (CPA) tests, respectively. The von Frey test, which allows 
to evaluate mechanical sensitivity, was performed at baseline (i.e. before paclitaxel 
injection) and from day 3 after the first injection onwards for a period of two months. The 
CPA test is an established rodent paradigm to detect aversiveness to a drug. The test 
was used to determine if the animals developed aversiveness towards paclitaxel. Basal 
and noxious-evoked activation of spinal dorsal neurons was assessed at one month after 
induction of the model by evaluating the expression of pCREB and c-Fos, respectively, 
by immunohistochemistry. The expression of c-Fos was evaluated after subjecting the 
animals to noxious cold at 0ºC. To study the descending noradrenergic pain modulatory 
system, we assessed the expression of dopamine-β-hydroxylase (DBH), a noradrenaline 
biosynthetic enzyme expressed in noradrenergic fibers at the spinal dorsal horn. The 
expression of DBH was evaluated by immunohistochemistry at one and two months after 
CIN induction. We also studied the expression and function of the α2-adrenergic receptor, 
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whose activation induces antinociceptive actions. The expression of the receptor was 
assessed by western blotting and immunofluorescence at one month after CIN induction. 
The function of the receptor was assessed by evaluating the effect of intrathecally 
administered clonidine, an α2-adrenergic receptor agonist, on pain behaviors. Clonidine 
was administered at 1 and 10 µg and its effects were evaluated on the von Frey and cold 
plate tests at one month after CIN induction.  
Our results showed that paclitaxel treatment induced mechanical allodynia early 
after initiation of the treatment and this behavior was maintained until the last time point 
tested at two months after CIN induction. Animals also showed aversiveness towards 
paclitaxel which remained until one week (last time point tested) after the last injection 
of paclitaxel. These results indicate that paclitaxel affects the sensorial component of 
pain, but also likely engages the affective/emotional component of pain as detected by 
the aversiveness induced by paclitaxel, leading to the development and maintenance of 
neuropathic like-behaviors. Our results also showed that while the expression of pCREB 
at basal levels was unaltered in comparison to DMSO-treated animals, c-Fos expression 
was increased upon noxious cold stimulation in paclitaxel-treated animals. The 
increased c-Fos expression is indicative of hypersensitivity of spinal dorsal horn neurons 
and is likely an indirect evidence of central sensitization. Our results further showed that 
DBH expression was increased at one month after initiation of the treatment, but not at 
two months. The expression of the α2-adrenergic receptor was unaltered. Clonidine 
induced antinociception with more pronounced effects in paclitaxel-treated animals. It 
remains to ascertain if DHB upregulation results in increased spinal noradrenaline levels, 
but the increase of α2-adrenergic receptor antinociceptive potency in paclitaxel-treated 
animals suggests the recruitment of descending noradrenergic inhibition probably to 
compensate for the increased spinal sensitization. 
Considering the scarce knowledge about how paclitaxel, through a peripheral 
action, engages the affective/emotional dimension of pain in non-verbal animals, future 
work should be developed to fully establish how paclitaxel affects this 
component/dimension of pain. It would also be interesting to continue studying the 
alterations in the descending noradrenergic modulatory system namely in what concerns 
the mechanisms underlying the phenomenon of potentiation of the α2-AR as this 
phenomenon reinforces the spinal noradrenergic antinociceptive activity. 
 
Keywords: Chemotherapy-induced neuropathy, paclitaxel, neuropathic pain, 
descending noradrenergic modulation, spinal sensitization, α2-adrenergic receptors 
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Resumo 
 
As drogas quimioterápicas são amplamente usadas no tratamento de cancro, 
mas os seus efeitos secundários debilitantes levam frequentemente a alterações na 
dosagem prescrita e à conclusão prematura do ciclo de tratamento, o que, em última 
análise, afeta a sobrevivência dos pacientes. A neuropatia induzida por quimioterapia 
(NiQ) é um dos efeitos secundários mais comuns do uso de drogas quimioterápicas. A 
NiQ resulta da ação adversa das drogas citostáticas nos nervos periféricos. O paclitaxel 
é um citostático comummente prescrito e conhecido pela sua ação danosa nos nervos 
sensoriais e por produzir dor neuropática caracterizada por hipersensibilidade mecânica 
e térmica. Os mecanismos moleculares responsáveis pelo desenvolvimento de NiQ pelo 
paclitaxel têm sido maioritariamente investigados ao nível do sistema nervoso periférico, 
mas os efeitos no sistema nervoso central ainda estão pouco estudados. Neste trabalho, 
estudou-se os efeitos do citostático paclitaxel ao nível da medulla espinhal, o primeiro 
local de transmissão de informação nociceptiva desde a periferia até ao cérebro. Três 
estudos foram incluídos na presente tese, cujos objetivos foram: i) determinar o início e 
a manutenção de comportamentos nociceptivos e aversivos; ii) avaliar a ativação basal 
e evocada por estímulo nóxico de neurónios do corno dorsal da medula espinhal; iii) 
estudar o sistema de modulação descendente noradrenérgico. 
Ratos Wistar machos adultos receberam injeções intraperitoneais de paclitaxel 
(Taxol®, 2.0 mg/kg) ou da solução veículo sulfóxido de dimetilo (DMSO) ou solução 
salina em quatro dias alternados. Os comportamentos nociceptivos e aversivos foram 
avaliados através dos testes de von Frey e de aversão condicionada de lugar 
(Conditioned Place Aversion – CPA), respetivamente. O teste de von Frey, que permite 
avaliar sensibilidade mecânica, foi realizado basalmente (isto é, antes das injeções de 
paclitaxel) e a partir do dia 3 após a primeira injeção até ao fim de dois meses. O teste 
de CPA é um estabelecido paradigma em animais roedores para detetar aversão a 
determinada droga. Este teste foi usado para determinar se os animais desenvolviam 
aversão ao paclitaxel. A avaliação da ativação basal e evocada por estímulo nóxico de 
neurónios espinhais do corno dorsal foi realizada um mês após indução do modelo de 
NiQ através da análise da expressão de pCREB e c-Fos, respetivamente, por 
imunohistoquímica. A expressão de c-Fos foi avaliada após sujeição dos animais a frio 
nóxico a 0ºC. Para estudar o sistema de modulação descendente noradrenérgico, 
avaliou-se a expressão da dopamina-β-hidroxilase (DBH), uma enzima biosintética de 
síntese de noradrenalina expressa em fibras noradrenérgicas no corno dorsal da medula 
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espinhal. A expressão de DBH foi avaliada por imunohistoquímica, um e dois meses 
após a indução de NiQ. A expressão e função do recetor α2-adrenérgico na medula 
espinhal, cuja ativação induz antinocicepção, também foram estudadas. A expressão do 
recetor foi determinada por técnicas de western blotting e imunofluorescência, um mês 
após indução de NiQ. A função do recetor foi avaliada através da análise do efeito da 
administração intratecal de clonidina, um agonista dos recetores α2-adrenérgicos, em 
comportamentos nociceptivos. A clonidina foi administrada nas doses de 1 e 10 µg e os 
seus efeitos foram avaliados nos testes de von Frey e de placa fria, um mês após 
indução de NiQ. 
 Os resultados mostraram que a administração de paclitaxel induziu alodínia 
mecânica logo após o início do tratamento e este comportamento foi mantido até ao 
último intervalo de tempo testado, isto é, dois meses após indução de NiQ. Os animais 
também mostraram aversão ao paclitaxel, um comportamento que se manteve até ao 
último intervalo de tempo testado, isto é, uma semana após a última injeção de 
paclitaxel. Estes resultados indicam que o paclitaxel afeta a componente sensorial da 
dor, mas provavelmente também a componente afetiva/emocional da dor, tal como 
detetado pela aversão induzida pelo paclitaxel, o que em última análise conduz ao 
desenvolvimento e manutenção de comportamentos de dor neuropática. Os resultados 
também demonstraram que, enquanto a expressão basal de pCREB pareceu inalterada 
em comparação com os animais tratados com DMSO, a expressão de c-Fos aumentou 
após estimulação fria nóxica em animais tratados com paclitaxel. O aumento da 
expressão de c-Fos é indicativo de hipersensibilidade dos neurónios espinhais do corno 
dorsal e é possivelmente uma evidência indireta de sensitização central. Os resultados 
mostraram, ainda, que a expressão de DBH surgiu aumentada, um mês após o início 
do tratamento, mas não aos dois meses. A expressão do recetor α2-adrenérgico não 
surgiu alterada. A clonidina induziu antinocicepção com efeitos mais pronunciados nos 
animais tratados com paclitaxel. Permanece por determinar se o aumento da expressão 
de DBH resulta num aumento dos níveis espinhais de noradrenalina, mas o aumento da 
potência antinociceptiva dos recetores α2-adrenérgicos em animais tratados com 
paclitaxel sugere o recrutamento de inibição descendente noradrenérgica 
provavelmente em compensação do aumento da sensitização espinhal. 
Considerando o escasso conhecimento sobre como o paclitaxel, através de uma 
ação periférica, é capaz de afetar a dimensão afetiva/emocional da dor em animais não-
verbais, trabalho futuro deve ser desenvolvido para inteiramente estabelecer como o 
paclitaxel afeta esta componente da dor. Seria igualmente interessante dar continuidade 
ao estudo sobre as alterações no sistema de modulação descendente noradrenérgico, 
nomeadamente no que respeita aos mecanismos inerentes ao fenómeno de 
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potenciação dos recetores α2-adrenérgicos, uma vez que este fenómeno reforça a 
atividade espinhal antinociceptiva noradrenérgica. 
  
Palavras-chave: Neuropatia induzida por quimioterapia, paclitaxel, dor neuropática, 
modulação descendente noradrenérgica, sensitização espinhal, recetores α2-
adrenérgicos  
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Introduction 
 
1. Pain  
 
1.1. Pain definition 
According to the International Association for the Study of Pain (IASP), pain is 
defined as an unpleasant sensory and emotional experience associated with actual or 
potential tissue damage or described in terms of such damage [1]. Nociception is the 
process of detection of noxious stimuli and the subsequent transmission of encoded 
information to the brain, which will then produce pain as a sensation [2]. Acute pain 
serves a protective role as it works to motivate individuals to react to a tissue-damaging 
stimulus, preventing further damage. It also motivates us to protect the damaged area 
and seek treatment [3, 4]. In some cases, pain may persist beyond the necessary time 
for tissue healing, rendering it no longer beneficial for the individual. On that note, pain 
is considered chronic if it persists longer than three months and its maintenance is due 
to changes that occurred to the nervous system in consequence of the tissue damage 
or it can also occur for no apparent pathophysiological reason (as in fibromyalgia) [5]. 
Risk factors such as genetic predisposition, age, gender and previous pain experience 
also likely play a part in the transition from acute to chronic pain [6]. 
 
 
1.2. Pain transmission 
 
In normal physiological conditions, the pain process begins after specialized 
peripheral sensory neurons called nociceptors detect high threshold physical (pressure 
and temperature) and noxious chemical stimuli extreme enough to potentially cause 
tissue injury and convert them into electrochemical signals [4]. Nociceptors, whose cell 
bodies are located in the dorsal root ganglia (DRG), ramify in the skin, muscle, 
connective tissue and internal environment of the organism such as the abdominal, 
pelvic and thoracic viscera. They initiate the transmission process of action potentials to 
the central nervous system, for which they are known as first order neurons [7]. There 
are two classes of first order nociceptive neurons, the myelinated Aδ- and unmyelinated 
C-fibers (Figure 1), and they differ on their diameter and conduction velocities. Although 
they are both slow conducting fibers, the fact that the Aδ-fibers are lightly myelinated and 
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have a larger diameter renders them faster than the C-fibers [8]. Because Aδ-fibers 
transmit nociceptive impulses quicker, they initiate the response to tissue injury and are 
responsible for sharp and localized pain. The unmyelinated C-fibers transmit the 
impulses more slowly and are, therefore, responsible for dull, aching and poor localized 
pain [9].  
 
 
Figure 1. Nociceptive pathways from the periphery to the brain. High threshold thinly myelinated Aδ and unmyelinated C 
nociceptor fibers (red box), whose cell bodies are localized in the DRG, detect, transduce and transmit information about 
noxious stimuli from peripheral tissues to the spinal dorsal horn, the first relay site in the transmission of nociceptive 
information. From the spinal cord, ascending neurons continue to transmit nociceptive signals, via the spinoreticular, 
spinothalamic and spinomesencephalic pathways (red and pink lines), to the several cortical and subcortical structures in 
the brain, in charge of further signal processing culminating in pain perception. Abbreviations: ACC, anterior cingulate 
cortex; BG, basal ganglia; C-LTMRs, C-type low-threshold mechanoreceptors; HT, hypothalamus; M1, primary motor 
cortex; PAG, periaqueductal grey; PB, parabrachial nucleus; PCC, posterior cingulate cortex; PFC, prefrontal cortex; S1, 
primary somatosensory cortex; SMA, supplementary motor area [10].  
 
 
Adequate intensity of noxious stimulation or the release of chemicals at the site 
of an injury excite the nerve endings of first order primary afferent neurons and 
nociceptive information is then transmitted to second order neurons primarily located in 
the superficial laminae I and II and lamina V of the spinal dorsal horn [4] (Figure 2). The 
spinal dorsal horn neurons within laminae I and II are responsive to noxious stimulation 
via Aδ- and C-fibers (high-threshold neurons), and neurons in laminae V receive both 
noxious and nonnoxious input via direct (monosynaptic) Aδ- and Aβ-fiber inputs, 
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respectively, and indirect (polysynaptic) C-fiber inputs. These neurons are called wide 
dynamic range (WDR) neurons since they respond to a broad range of stimuli intensities. 
Neurons in laminae III and IV are primarily responsive to innocuous stimulation via Aβ-
fibers (Figure 2) [11, 12]. The central projections of first order neurons can also synapse 
with inhibitory or excitatory interneurons that work to modulate nociceptive information 
before being further transmitted to the brain by second order neurons [7] (Figure 2).  
The axons of second order neurons ascend to the brain, via the spinothalamic 
tract, to the thalamus (an important supraspinal pain processing center), or via the 
spinoreticular tract to the brainstem reticular formation before the nociceptive information 
is transmitted to the thalamus (Figure 1). At the thalamus, the nociceptive information is 
sent to the somatosensory (involved in the memory of sensory input) and prefrontal 
cortices, via third order neurons, for encoding and perception of the pain experience [13] 
(Figure 1). The reticular formation sends fibers transmitting nociceptive input no only to 
the thalamus but also to the hypothalamus, which is involved in the autonomic and reflex 
responses, and the limbic system, which encodes the emotional component of 
nociception (Figure 1). 
 
 
Figure 2. Spinal projections of primary sensory neurons. Unmyelinated peptidergic C-fibers, which release substance P, 
and calcitonin-gene related peptide (CGRP), and myelinated Aδ-fibers terminate mainly at the superficial dorsal horn 
where they synapse with high-threshold projection neurons in lamina I (red) and interneurons in lamina II (green). Aδ-
fibers also converge on projection neurons of the wide dynamic range type in lamina V (purple). Large myelinated Aβ-
fibers, which carry innocuous input, terminate on lamina III [11]. 
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1.3. Pain modulation 
 
1.3.1. The endogenous pain control system 
The transmission of pain signals at the spinal cord can be altered by a complex 
process known as endogenous pain modulation. About 85% of the ascending axons of 
second order neurons in the spinal cord project to the brainstem reticular formation (via 
the spinoreticular tract), which includes areas in charge of pain modulation, such as the 
dorsal reticular nucleus (DRt), the rostral ventromedial medulla (RVM), the noradrenergic 
locus coeruleus (LC) and the periaqueductal gray region (PAG) [7, 14] (Figure 3). 
Descending axonal projections from these pain modulatory centers to the spinal cord 
modulate the spinal nociceptive transmission [15, 16] (Figure 3). This modulatory 
process, also known as descending pain modulation, works to inhibit or facilitate spinal 
nociceptive processing which ultimately controls the experience of pain. Descending 
modulation serves an evolutionary purpose important for survival and its activation 
depends on the emotional and cognitive states and level of arousal [17]. During stressful 
or threatening situations, descending inhibitory control of pain is activated to allow 
escape and protection. In such situations, the PAG, which receives projections from 
regions associated with the processing of emotions (including the hypothalamus, 
amygdala, and prefrontal cortex), forms excitatory synapses with the serotonin-releasing 
neurons of the raphe nucleus magnus and the nucleus gigantocellularis localized in the 
RVM, which ultimately project to the spinal dorsal horn [14]. The RVM mediates a 
bidirectional control of nociception by its resident on-cells, off-cells, or neutral-cells. 
Activation of the on-cells enhances firing as well as the intensity of the nociceptive 
response to noxious stimulation. Activity of the off-cells exerts antinociception. Activity of 
neutral-cells was found not to correlate with nociceptive stimuli. These cells are not 
serotonergic but they can modulate serotonergic neurons of the raphe nucleus magnus 
and the nucleus gigantocellularis. Once serotonin is released in the spinal dorsal horn, it 
plays inhibitory or facilitatory actions depending on the receptor subtype activated [14]. 
The PAG and RVM also project to noradrenergic areas (Figure 3) which in turn send 
projections to the spinal dorsal horn where they exert antinociception [18].  
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Figure 3. Pathways and brain regions involved in the transmission and modulation of pain signals. Nociceptive information 
ascending from the spinal cord is transmitted to the thalamus and to brainstem structures (medulla oblongata, pons and 
mid brain), including the rostral ventral medulla (RVM) and the periaqueductal grey (PAG). The thalamus projects to 
cortical (somatosensory, anterior cingulate, insular and prefrontal cortices) and subcortical (amygdala, nucleus 
accumbens) areas, which are involved in the processing of nociceptive information into a sensation. These brain regions 
project to the PAG, which in turn projects to the serotoninergic raphe nuclei of the RVM and noradrenergic locus coeruleus. 
Descending pain modulatory projections from these sites to the first synapses in the spinal cord modulate nociceptive 
transmission [16]. 
 
 
1.3.2. Descending noradrenergic pain modulation 
Three brainstem noradrenergic cell groups, the locus coeruleus (or A6 
noradrenergic cell group), the A5 and A7 noradrenergic cell groups, are the main sources 
of noradrenergic projection to the spinal cord [19]. Descending noradrenergic fibers 
release noradrenaline at the spinal cord where it mainly exerts an inhibitory action at the 
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level of the afferent nociceptive terminals or spinal dorsal horn neurons (pre- and 
postsynaptic inhibition, respectively) via activation of α2-adrenergic receptors (α2-AR) 
[20].  
Alpha-adrenergic receptors are pharmacologically subdivided into α1 (further 
subdivided into α1A, α1B and α1D subtypes) and α2 (further subdivided into α2A, α2B and α2C 
subtypes) adrenergic receptors belonging to the group A rhodopsin-like G protein-
coupled receptor class [21]. Located in the dorsal root ganglion and in the spinal dorsal 
horn, α1-AR are coupled to phospholipase C through Gq and its activation by 
noradrenaline increases spinal and presynaptic neuronal excitability hence facilitation of 
nociceptive transmission [22]. The α2-AR are located on terminals of noradrenergic 
descending fibers (autoreceptors), on local spinal neurons, on central terminals of 
primary afferent nociceptors and on dorsal root ganglia [20]. They are negatively coupled 
to adenylate cyclase through Gi proteins and when activated, they exert an inhibitory 
action on neurotransmitter release by reducing the formation of cyclic AMP and calcium 
influx during an action potential. When noradrenaline is released from descending fibers, 
it suppresses pain by acting on the different subtypes of spinal α2-AR. The α2A-AR 
subtype is markedly expressed in noradrenergic descending fibers and its activation 
inhibits noradrenaline release to spinal neurons [21]. They are also expressed on central 
terminals of primary afferent neurons containing the excitatory neurotransmitters 
substance P and glutamate and upon activation of α2A-AR, the presynaptic inhibition of 
the release of these substances promotes antinociception [23]. The α2C-AR are located 
presynaptically on DRG terminals and postsynaptically on terminals of spinal excitatory 
interneurons which innervate second order neurons. Activation of postsynaptic α2C-AR 
inhibits transmission of nociceptive input to ascending neurons projecting to the 
supraspinal pain processing areas [24]. The α2B-AR appears to be the least expressed 
α2 subtype in the spinal cord and primary afferent neurons of postnatal animals. 
 
1.4. Affective dimension of pain 
Composed of both sensorial and affective dimensions, pain is considered a 
negative affective (unpleasant) state that works not only to motivate animals to maintain 
homeostasis by escaping/avoiding harmful situations (e.g. injuries, noxious stimuli) or to 
seek relief but also to promote learning about the outcome of those situations that might 
present again in the future [25]. Several corticolimbic regions integrate the brain circuit 
involved in encoding nociceptive signal valuation, pain-motivated decision-making and 
learning (Figure 4). One such area is the dopaminergic nucleus accumbens (NAc), which 
signals affective value and saliency of noxious stimuli [26]. The NAc receives projections 
from dopaminergic neurons in the ventral tegmental area (VTA). Natural rewards such 
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as pain relief activates these mesolimbic neurons and elicit dopamine release in the NAc. 
VTA dopaminergic inputs to the NAc signal saliency, as well as the value of pain or relief. 
Reward-related information is also encoded in frontal lobe areas, specifically in the 
anterior cingulate cortex (ACC), lateral orbitofrontal cortex (OFC), and ventromedial and 
anterior prefrontal cortices (PFC). The connections between these prefrontal, 
orbitofrontal and anterior cingulate cortices and the mesolimbic dopaminergic neurons 
contribute to affective, emotional and cognitive control of pain perception and are 
involved in motivational decision-making [25]. Chronic pain states are characterized by 
anatomical and functional reorganization of the corticolimbic circuit. 
 
 
Figure 4. Corticolimbic circuit involved in the enconding of the sensory-discriminative and affective/emotional aspects of 
pain. The dopaminergic NAc plays a role in reward-motivated behavior by encoding quantitative reward prediction error, 
which is important for learning and decision-making in relation to noxious stimuli. Reward-related information is also 
encoded in the ACC, OFC and PFC. These structures contribute to affective, emotional and cognitive control of pain 
perception and are involved in motivational decision-making [25].  
 
 
 
In chronic pain states, both nociceptive signaling and associated 
affective/emotional and cognitive functions are altered. This emotional component of 
pain does not receive much attention in animal studies of chronic pain, more so because 
of the lack of experimental tools for these types of studies. One such tool that has been 
gaining attention is the conditioned place aversion (CPA) paradigm. The CPA paradigm 
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is an operant model used to assess escape/avoidance behaviors under the principle that 
animals, once taught how to associate an environment to the feeling of unpleasantness 
derived from a painful situation, will exhibit an escape response towards an alternative 
environment that they learned not to be associated with pain [27, 28]. In that case, it is 
possible to study the affective component of pain originating from noxious stimulation 
(thermal, mechanical or chemical) or from spontaneous neuronal discharge (chronic 
ongoing pain). The formalin test (a noxious chemical stimulus) in the context of the 
conditioning-place paradigm is very commonly used to distinguish pain emotion from 
pain sensation in rats [29]. More than eliciting nociceptive behavior, such as lifting 
responses, subcutaneous injection of dilute formalin produces CPA (F-CPA), which 
means that animals learn about its aversiveness similarly as humans learn about the 
outcome of a noxious stimuli [30]. One of the best-known brain areas to be involved in 
processing information related to pain-derived unpleasantness is the ACC. Neurons in 
the ACC were found to be necessary for the acquisition of CPA elicited by nociceptive 
stimulus such as formalin injection, seen as lesions of the rostral ACC reportedly reduced 
F-CPA by reducing the aversiveness or perceived unpleasantness of the stimulus, 
without reducing formalin-induced nociceptive behaviors [30]. In a model of chronic 
inflammatory pain, repeated activation of ACC neurons resulting from persistent 
peripheral nociceptive input has been shown to serve as an aversive teaching signal, 
leading animals to display generalized increased aversive responses to noxious stimuli 
[31]. Imaging and neurophysiologic studies revealed increased activity in the ACC in 
patients and animal models of neuropathic pain. One such study found enhanced 
affective pain ratings in response to noxious heat in diabetes patients with neuropathic 
pain consistent with augmented cerebral activity in the ACC [32]. In chemotherapy-
induced neuropathic pain, which is the main subject of this thesis, little is known about 
the affective component of pain in animals, but in humans the painful symptoms are often 
accompanied by mood disorders such as depression [33].  
 
 
 
 
 
 
 
 
 
 
FCUP 
Study of descending noradrenergic pain modulation in a model of neuropathic pain induced by chemotherapy 
20 
 
 
 
 
2. Types of pain 
 
2.1. Nociceptive pain 
Nociceptive pain is a fundamental type of pain and overall an important 
physiological process for homeostasis. It serves as a warning sign for animals to 
withdraw from noxious peripheral stimulation and pay special care to an injured site in 
the body, at the same time serving as a teaching signal about the outcome of similar 
harmful situations in the future [25]. Information about the nature, intensity and duration 
of peripheral noxious stimulation travels from peripheral nerve endings of Aδ- and C-
fibers which upon noxious stimulation release neurotransmitters like the excitatory amino 
acids glutamate and aspartate, calcitonin gene-related peptide (CGRP), substance P 
(SP) and neuropeptide Y (NPY) at the spinal dorsal horn. Second order neurons in the 
spinal cord then continue the transmission process through ascending projections to the 
brain, which in turn will interpret the nociceptive signals and produce the pain experience 
[34]. The benefits of nociception cease the moment it becomes permanent as a result of 
disease processes directly or indirectly affecting the nerves [35].  
 
2.2. Inflammatory pain 
Inflammatory pain occurs following activation of the inflammatory process upon 
tissue damage. The underlying release of sensitizing inflammatory mediators, including 
bradykinin, prostaglandins, H+, ATP, nerve growth factors, pro-inflammatory cytokines 
and interleukins by infiltrating immune cells such as macrophages, T-cells, mast cells 
and neutrophils leads to activation of receptors in the nociceptors innervating the 
damaged tissue [36]. As a consequence of increased ambient inflammatory mediators, 
there is a reduction in the activation threshold of the Aδ- and C-fibers upon noxious 
stimulation [37]. One of the features of inflammatory pain states is that normally 
innocuous stimuli produce pain because low-threshold Aβ-fibers, that normally only 
conduct innocuous tactile stimuli, are sensitized by these inflammatory mediators as well 
[38]. The peripheral sensitization process during inflammation is important for optimal 
healing, because it motivates protection behaviors of the injured area as well as 
prevention from contact or movement to reduce further damage and pain [37]. Spinal 
cord neurons are also more excitable and amplify ascending inputs to the brain. The 
changes in neuronal sensitivity following inflammation are generally reversible and 
sensitivity will most likely be restored when the inflammation has disappeared. However, 
repetitive nociceptive stimulation, whether being inflicted in previously inflamed 
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peripheral tissues or new ones, may result in a prolonged inflammatory process through 
activation of lymphocytes and release of tumor necrosis factor (TNF-α) and interleukins 
IL1, IL6, and IL1β, which eventually leads to chronic inflammatory pain and subsequent 
aggravation of neuronal sensitization [39]. 
 
2.3. Neuropathic pain 
Neuropathic pain is defined as pain resulting from abnormal activity of neuronal 
tissues, either of the peripheral and central nervous systems, due to disease, injury or 
dysfunction, which can lead to a persistent pain state [5]. Abnormal signals may arise 
directly from injured axons and/or from the intact nociceptors that share their innervation 
territory [40]. Peripheral and central sensitization mechanisms are at the basis of altered 
neuronal activity. This type of pain is distinct from the inflammatory pain as the latter 
arises from intact nociceptive signaling pathways [37]. There is neuronal sensitization 
occurring during inflammatory pain, but it is for securing optimal healing conditions, while 
in neuropathic pain there is no benefit in neurons being sensitized. Inflammation is a 
component process seen in neuropathic pain, but it is one of the many sources of 
increased neuronal excitability in neuropathic pain.  
There are two types of neuropathic pain: peripheral and central neuropathic pain 
and they differ on the location of the nerve lesion. 
 
2.3.1. Peripheral neuropathic pain 
A peripheral neuropathy is described as a painful and debilitating condition 
caused by disease or direct damage inflicted on peripheral nerves. The leading causes 
of nerve damage include disease processes such as diabetes, traumatic nerve injuries 
and exposure to neurotoxic compounds, such as chemotherapeutic drugs [41]. Diabetic 
neuropathy manifests due to complex metabolic modifications in the organism that lead 
to neuronal impairment [42] Traumatic events like vehicle accidents, sports injuries and 
surgical procedures can cause nerve injury by compression or severing and such 
physical damage may ultimately result in loss of nerve function and cause neuropathy 
[41]. Chemotherapeutic drugs, which are administered to patients with cancer for their 
ability to disrupt the division and growth processes of cancer cells, often cause damage 
to peripheral nerves.  
In any presentation of peripheral neuropathy, symptoms develop according to the 
type of nerve that has been damaged. Patients with neuropathy can experience positive 
and negative sensory symptoms, motor symptoms and/or autonomic symptoms. Positive 
sensory symptoms range from numbness and tingling to neuropathic pain manifested as 
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intense pain episodes without any seeming provocation (spontaneous pain), pain to 
tactile and thermal stimuli that would not otherwise be felt (allodynia) and enhanced pain 
sensation after a painful stimulus (hyperalgesia) [4]. The negative sensory symptoms 
include an overall loss of stimuli perception (e.g. tactile and thermal). Motor symptoms 
include muscle weakness and wasting [43]. And the autonomic symptoms are mainly 
related to cardiovascular (blood pressure oscillations), gastrointestinal (constipation) and 
urological (urinary retention) abnormalities [44].  
The painful symptoms of peripheral neuropathy develop due to peripheral and 
central sensitization mechanisms. In peripheral sensitization, nociceptors become 
hypersensitive due to several molecular changes following damage, such as formation 
of new channels and altered gene expression culminating in altered receptor protein 
expression and activity. Notably, expression of voltage-gated sodium channels, which 
form clusters that accumulate at the site of injury and proximally within the intact dorsal 
root ganglion, lead to ectopic firing and lowering of the action-potential threshold [45]. 
Damage to peripheral nerves also induces upregulation of receptor proteins such as the 
Transient receptor potential vanilloid 1 (TRPV1) in A- and C-fibers, which contributes to 
enhanced responses to noxious heat (heat hyperalgesia) [46]. There is also release of 
proinflammatory cytokines, chemokines and neurotrophic factors from immune cells. All 
of these alterations contribute to hyperexcitability of A- and C-fibers [47]. The amplified 
pain signals from the periphery alter the sensitivity of spinal dorsal horn neurons, leading 
to central sensitization. Central sensitization corresponds to an enhancement in the 
activity of neurons and circuits in nociceptive pathways caused by increases in 
membrane excitability, synaptic efficacy and reduced inhibition [48]. Due to central 
sensitization, nonpainful peripheral stimuli are interpreted as painful and peripheral 
noxious stimuli are interpreted as overly painful.  
 
2.3.2. Central neuropathic pain 
Central neuropathic pain occurs due to insult to the spinal cord, brain or 
brainstem. The main sources of injury include ischemic or hemorrhagic strokes, 
infections, demyelinating multiple sclerosis, traumatic spinal cord or brain injury, and 
cancer [49]. Central neuropathic pain stems from impairment within somatosensory 
pathways. Indeed, dysfunction of spino-thalamic-cortical pathways results in impaired 
pain in response to pinprick and temperature sensation in a neurologically affected 
painful limb [50]. Regarding pathophysiology of central neuropathic pain, intact 
spinothalamic tract neurons become hyperexcited and chronically activated at the level 
of the spinal cord injury (SCI) site, directly via microglial activation and/or via disruption 
of descending inhibition. Disinhibition is also associated with lesions of the thalamus, for 
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which there is disruption of GABAergic neurons and increased sensory input to cortical 
regions resulting in painful sensation [51]. Spontaneous activity has also been reported 
in deafferented thalamic regions during central poststroke pain (CPSP) and in the intact 
thalamus following SCI [52, 53].  
 
 
3. Chemotherapy-induced peripheral neuropathic pain 
 
3.1. Epidemiology, symptoms and treatments 
In the current century, the estimate of individuals that successfully underwent 
chemotherapy for treatment of hematological and solid tumors is, as of 2013, over 25 
million worldwide [54]. The incessant effort to improve the effectiveness of 
chemotherapeutic drugs while reducing their inherent side-effects explains the observed 
survivorship rates. However, there is much concern about the adverse effects at the 
whole-body level. One of the most problematic side-effects of chemotherapeutic 
treatment is the onset of peripheral neuropathy, which may begin early on or long after 
treatment [55] and estimates show that 30 to 40 percent of cancer patients develop this 
chemotherapy-related complication that limits both drug dose and duration of treatment 
[41]. 
Chemotherapy-induced neuropathy (CIN) is a condition that develops from 
damage to peripheral nerves inflicted by chemotherapeutic drugs and that interferes with 
the active treatment of cancer by forcing dosage reduction, treatment delay or premature 
cessation. More than hindering the battle against cancer, CIN produces a set of 
symptoms with variable levels of severity that reduce the quality of life of cancer patients 
[56]. Anticancer drugs can harm any of the peripheral nerves (sensory, motor and 
autonomic), especially sensory and autonomic nerves given their anatomical location 
outside the blood-brain barrier. The reason is that capillaries with fenestrated and leaky 
walls supply these neurons allowing for the passage of exogenous toxic substances from 
the circulation (in contrast to what happens in the brain and spinal cord) and making 
them very susceptible to damage [57]. The way these neurotoxic drugs interfere with 
peripheral nerve function may be through perturbation of metabolic processes inside 
neuronal cell bodies, impairment of axonal transport by microtubule disruption and 
activation of apoptosis pathways in consequence of DNA damage [58].  
CIN symptoms may present at any time after initiation of the treatment or even 
weeks to several months after its completion, depending on the extent of damage [59]. 
Particularly, sensory symptoms are generally the most prominent, with pain, tingling, 
numbness and loss of sensibility being often present in the lower and upper limbs [60]. 
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Motor symptoms are not very common and it is not well known why motor nerves are 
less affected [61], but in some cases, muscle cramps in the forearm and hands may be 
experienced and in the worst cases (which are rare), they can progress to paralysis. 
Unlike the sensory symptoms, autonomic symptoms are infrequently seen in CIN, though 
both types of nerves are vulnerable to damage given their location outside the blood-
brain barrier. The reason for this is that it takes only a small loss of sensory neurons or 
axons to produce the typical associated symptoms than to disrupt organ function [62]. 
The severity and duration of CIN symptoms vary among patients and depend on 
factors such as the drug dose per cycle of treatment, the cumulative dose in the body 
over time, the frequency of its administration, the nature of the drug and predisposing 
factors such as a history of pathology in the nerves [62, 63]. Before initiating 
chemotherapy, the treatment is established based on the type of cancer and its stage of 
development and also based on the response rate to a particular chemotherapeutic drug 
or combination of drugs [64]. When it comes to drug dosage, a high dose of the drug 
may be prescribed for cancers in advanced stages in order to increase chances of 
survival. However, studies on patients with ovarian cancer, for example, show that 
increasing dose intensity per cycle shows no benefit in survival when compared to a low 
dose per cycle regimen [65] and leads to a more severe neuropathy, that often starts in 
a few days after initiation of the treatment [66]. On the other hand, when patients receive 
a low dose per cycle, they usually show longer overall survival and present mild 
neuropathic symptoms. Nevertheless, receiving a low dose per cycle means receiving it 
on a weekly basis and such frequency increases neurotoxicity and the risk of developing 
neuropathy due to higher cumulative doses in the body [59]. When it comes to choosing 
which drug to use in the treatment, special attention is paid to the information on the 
cancer and response rates as well as the nature of the drug and how severe its 
neurotoxic effects can be.  
The cytostatic agents known to induce CIN are the platinum agents (cisplatin, 
carboplatin and oxaliplatin), anti-tubulin (paclitaxel, docetaxel and vincristine) and the 
proteasome inhibitor bortezomib. Given their individual structural properties, these 
agents promote different pathological processes on peripheral nerves, causing a 
dissimilar degree of damage which subsequently influences the severity of CIN 
symptoms [63] (Figure 5). 
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Figure 5. Chemotherapy toxicity in the peripheral nervous system. Several chemotherapeutic drugs have been shown to 
affect the distal nerve terminals, axons and its components (myelin, microtubules, mitochondria, ion channels and vascular 
network) and dorsal root ganglia, all of which lead to peripheral sensitization and painful neuropathy [55]. 
 
 
3.2. Pathophysiology of paclitaxel-induced neuropathic pain 
Paclitaxel is a taxane-derived chemotherapeutic agent that was first isolated from 
Taxus brevifolia and is now extensively used for the treatment of breast, ovarian and 
non-small cell lung carcinomas. The drug exerts its antineoplastic effects by binding to 
β-tubulin of microtubules in cancer cells, preventing depolymerization, blocking the 
progression of the cell cycle and inducing apoptosis [67]. The best-known side-effects of 
paclitaxel arise from damage to peripheral sensory nerves which ultimately leads to the 
development of peripheral neuropathy. 
Several studies have been conducted to investigate the pathological processes 
initiated by paclitaxel within the pain modulatory system, some of which have used 
animal models treated with different regimens of paclitaxel to mimic the paclitaxel-
induced neuropathic pain condition in humans. In vitro studies have demonstrated that 
paclitaxel causes microtubule dysfunction in cultured sensory neurons by promoting 
microtubule stabilization, condensation and reorientation [68, 69], which in turn causes 
disruption of axoplasmic organelle transport, abnormal neurite outgrowth, demyelination 
and neuronal death [66]. In vivo studies using rodent models have demonstrated that 
paclitaxel causes degeneration of peripheral terminal arbors of sensory neurons in the 
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hind paw skin of rats, which originates spontaneous discharge and mechanical and 
thermal hypersensitivity [70]. Paclitaxel is also known to promote axonal mitochondrial 
swelling through a calcium efflux mechanism [71], contributing to hyperexcitability of 
nociceptors which results in mechano-allodynia and mechano-hyperalgesia. The drug 
also increases the expression and activity of the Transient receptor potential vanilloid 
subtype 1 (TRPV1) ion channel in rat and human DRGs, leading to increased pain 
signaling that ultimately results in thermal hyperalgesia [72]. At last, paclitaxel promotes 
the release of proinflammatory cytokines upon astrocyte activation in the spinal cord and 
macrophage activation in the DRG, which lead to nociceptor sensitization [68]. 
Differences in the severity of pathological, electrophysiological and behavioral 
abnormalities produced by paclitaxel have been reported among regimens and animal 
models used. Paclitaxel administration in rats at high dosing regimens of 16 mg/kg once 
a week for 5 weeks or 2 doses of 12-18 mg/kg 3 days apart produced mitochondrial 
swelling, axonal loss and slow conduction velocities in sensory and motor nerves that 
persisted for 4 months with no abnormalities to thermal sensation [73]. Lower doses 
given to rats intraperitoneally (0,5-2,0 mg/kg) every other day for a total of 4 injections 
produced no impairment in motor function and degeneration of sensory and motor axons, 
but resulted in heat-hyperalgesia, mechano-allodynia, mechano-hyperalgesia and cold 
allodynia which resolved in a few weeks [74, 75]. Other studies using mouse models 
have reported a dependence of the neuropathic phenotype on the genetic background 
of the mice since the same dose of paclitaxel was shown to produce different effects and 
did not result in any neuropathic behavior in some mice strains [75]. 
The majority of these studies have looked at the pathophysiological processes 
induced by paclitaxel occurring in the peripheral nervous system. But even though 
paclitaxel does not seem to cross the blood-spinal cord barrier, it likely causes 
peripherally-mediated alterations in the spinal cord by enhancing the nociceptive input 
from the functionally-impaired and hypersensitive nociceptors into second-order neurons 
and/or interneurons and by promoting the activation of glial cells, as described in other 
neuropathic pain models [10]. Namely, there is an activity-dependent increase in the 
density of synaptic spines in dendrites of spinal neurons that leads to hypersensitivity 
(structural plasticity) [76]; also, the increased incoming afferent activity can deregulate 
spinal interneurons causing a disturbed balance between spinal excitation and inhibition 
of pain signals (functional plasticity). Additionally, in a peripheral nerve transection 
model, damage to first-order neurons was shown to initiate central immune signaling first 
by activation of microglia and then astrocytes, both of which release proinflammatory 
cytokines such as interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α 
(TNF-α) that diffuse and bind to receptors on presynaptic and postsynaptic terminals in 
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the spinal dorsal horn to control excitatory and inhibitory synaptic transmission [13, 77]. 
These and other glia-derived mediators have been shown: i) to increase excitatory 
synaptic transmission at central terminals by enhancing glutamate release, which 
contributes to the development of central sensitization and pain behaviors; and ii) to 
reduce the activity of inhibitory interneurons or inhibitory descending projections, causing 
nociceptive hypersensitivity [10, 13].  
In the paclitaxel model, recent studies using the rat model of paclitaxel-induced 
neuropathy have reported signaling alterations in the spinal cord, namely an increase in 
TRPV1 expression on spinal terminals of primary afferent neurons in animals with 
thermal hypersensitivity [72] and decreased expression of glutamate transporters in 
spinal astrocytes, which fails to clear excitatory glutamate from synapses and induces 
spontaneous nociceptive behaviors and hypersensitivity [78]. However, little is still 
known about the mechanisms of neuronal plasticity and glial cell functioning during 
neuropathy at the level of the spinal cord. 
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Aims and methodologies 
 
 
The pathophysiological mechanisms at the central nervous system leading to the 
development of neuropathic pain during and after chemotherapeutic treatment with 
paclitaxel are still understudied. The main purpose of this thesis was to study the 
alterations that the chemotherapeutic agent paclitaxel produces in the descending 
noradrenergic modulatory system. For that, we used a rat model replicating CIN induced 
by paclitaxel. The research work conducted for this thesis was comprised of three parts: 
i) behavioral characterization of paclitaxel-induced neuropathic pain; ii) study of the 
activation patterns of superficial and deep spinal dorsal horn neurons induced by 
paclitaxel treatment; and iii) study of the descending noradrenergic modulatory system 
in paclitaxel-treated rats, the main focus of the thesis. 
First, we studied the effects of paclitaxel in mechanical sensitivity and in the 
affective/emotional component of pain. For that, CIN was induced by administering four 
intraperitoneal injections of paclitaxel at 2.0 mg/kg on four alternating days [74]. To 
determine the onset and maintenance of mechanical sensitivity in paclitaxel-treated 
animals, we used the von Frey test which was performed prior to initiation of the 
treatment and several days after initiating the treatment, for two months. To study the 
affective/emotional component of pain, we aimed at assessing if animals developed 
escape or avoidance behaviors towards receiving paclitaxel as they were conditioned in 
an environment with specific cues that allowed them to associate the physical space to 
the feeling of receiving the drug. For that, we used a variation of the Conditioned Place 
Preference (CPP) test, an established rodent paradigm of drug reward, which was the 
Conditioned Place Aversion (CPA) test. The tests differ only on the feeling that the drug 
under study triggers on animals. In our case, we aimed at determining whether paclitaxel 
induced aversive-like behaviors. 
The second goal of the present thesis was to evaluate the activation patterns of 
spinal dorsal horn neurons in paclitaxel-treated rats by studying the expression of two 
markers of neuronal activation: pCREB and c-Fos. The spinal expression of pCREB has 
been reported to be activated after nerve injury in several neuropathic pain models and 
is known to be driven by ongoing abnormal afferent input, rendering it important for 
maintaining central sensitization [79]. C-fos is a proto-oncogene whose protein product, 
c-Fos, is used as a marker for the activation of nociceptive neurons in the superficial and 
deep spinal dorsal horn of rats following depolarization after a noxious stimulus [80]. In 
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normal conditions, there is a direct correlation between the levels of c-Fos expression 
and the intensity of the noxious stimulation. In pathological conditions, a low-intensity 
innocuous stimulus is sufficient to elicit neuronal activation [81]. We aimed at assessing 
the basal expression of pCREB in the dorsal horn of the spinal lumbar L4 segment by 
immunohistochemistry, at one month after CIN induction. We aimed at determining the 
expression of c-Fos after noxious cold stimulation, in the dorsal horn of the spinal lumbar 
L4 segment by immunohistochemistry at one month after CIN induction. We selected the 
one-month time point for this analysis because it is reported in the literature as the peak 
of pain severity in this animal model [71]. 
The third goal of this thesis was to study the descending inhibitory noradrenergic 
pain modulation during CIN induced by paclitaxel treatment. Based on animal studies of 
other types of peripheral nerve injury, it is thought that one of the underlying mechanisms 
for the development of the typical painful symptoms in neuropathic pain (ongoing or 
spontaneous pain, allodynia and hyperalgesia) is loss of inhibition of nociceptive 
transmission, either by physical loss of inhibitory neurons or changes in the activity of 
pain inhibitory pathways [10]. In normal conditions, the activation of the presynaptic α2-
adrenergic receptors (ARs) on central terminals of primary afferent nociceptors in the 
spinal cord by noradrenaline inhibits the presynaptic release of excitatory 
neurotransmitters responsible for transmission of pain signals [20]. In neuropathic 
conditions, this inhibitory mechanism is presumably lost which may account for the 
manifestation of the painful symptoms [82]. Here we aimed at evaluating the 
noradrenergic innervation in the spinal dorsal horn and then the expression and function 
of the presynaptic α2A-AR subtype. The noradrenergic innervation was evaluated at the 
spinal dorsal horn of L4 and L5 segments by immunohistochemical detection and 
quantification of the noradrenaline biosynthetic enzyme dopamine-β-hydroxylase (DBH), 
at one and two months after initiation of paclitaxel treatment. DBH is a highly-used 
marker of pontospinal noradrenergic innervation [83, 84]. The α2A-AR expression was 
assessed by western blotting and immunofluorescence in the same lumbar segments of 
the spinal cord at one month after CIN induction. The function of α2A-AR was assessed 
by studying behavioral nociceptive responses of the rats after intrathecal administration 
of two doses of the α2-AR agonist clonidine which mimics the effects of spinally released 
noradrenaline. The effects of clonidine were evaluated on evoked pain by the von Frey 
and Cold Plate tests which assess mechanical and cold allodynia, respectively. 
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Materials and Methods 
 
1. Animals 
Adult male Wistar rats (Charles River, France) were used in this study. The 
animals were pair-housed in plastic cages at 22 ± 2ºC and 55 ± 5% humidity in a 12/12h 
light/dark cycle. The animals had unrestricted access to food and water. Upon arrival, 
rats were allowed one week of acclimation before any procedure. 
All experiments were conducted following the ethical guidelines of the European 
Community Council Directive 2010/63/EU and of the International Association for the 
Study of Pain in conscious animals [85]. 
 
 
2. Induction of chemotherapy-induced neuropathy and 
experimental design 
Chemotherapy-induced neuropathy (CIN) was induced in animals weighing 175-
190 g by four intraperitoneal (i.p.) injections of paclitaxel (Taxol®, Tocris Bioscience, 
United Kingdom) at a dose of 2.0 mg/kg in four alternating days (1, 3, 5 and 7) as 
previously described by Polomano et al. (2001) [74]. Stock solutions of paclitaxel were 
prepared according to supplier’s standard recommendations by dissolving 50 mg of 
paclitaxel in 1 ml dimethyl sulfoxide (DMSO, Sigma-Aldrich®, USA) with gentle agitation 
at 37ºC. The stock solutions were aliquoted and stored at -20ºC. Before administration 
of paclitaxel, the aliquots were thawed and diluted in saline solution (NaCl 0,9%) at 37ºC 
with gentle agitation to a final concentration of 2.0 mg/ml of paclitaxel and 4% DMSO. 
Control animals were either treated with the vehicle solution 4% DMSO (DMSO group) 
or 0.9% NaCl (saline group).  
CIN was induced in six different experimental groups in order to perform 
behavioral, immunohistochemical and western blotting analysis (scheme 1). The 
behavioral studies aimed at evaluating nociceptive and aversive behaviors. The 
experimental group 1 (paclitaxel n = 6, DMSO n = 5, saline n = 5) was used to evaluate 
mechanical sensitivity for a period of two months following CIN induction (scheme 1). 
The experimental group 2 (paclitaxel n = 2, DMSO n = 1) was used to assess aversive 
behaviors (scheme 1). 
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The experimental group 3 was used to study the effects of spinal α2A adrenergic 
receptor (α2A-AR) activation on nociceptive behaviors, at one month after CIN induction. 
For this, we used paclitaxel- (n = 19) and DMSO-treated (n = 22) animals, submitted to 
an intrathecal surgery for implantation of a catheter in the lumbar segment of the spinal 
cord through which the α2-AR agonist clonidine was administered (scheme 1).  
Immunohistochemical analyses were performed to analyze the expression of 
DBH, pCREB, α2A-AR and c-Fos at the spinal dorsal horn. These analyses were 
performed upon vascular perfusion and spinal cord dissection (scheme 1). The 
expression of DBH was analyzed at two different time points, one and two months after 
CIN induction. The experimental group 1 was used to analyze DBH expression at the 
two-month time point (scheme 1). The experimental group 4 (paclitaxel n = 6, DMSO n 
= 6, saline n = 6) was used to analyze the one-month time point (scheme 1). The 
experimental group 4 was also used to analyze the expression of pCREB and α2A-AR. 
The experimental group 5 (paclitaxel n = 3, DMSO n = 4), which was submitted to noxious 
cold stimulation prior to vascular perfusion, was used to analyze the expression of c-Fos 
(scheme 1).  
The expression of the α2A-AR at the spinal dorsal horn was also evaluated by 
western blotting analysis. The experimental group 6 (paclitaxel n = 5, DMSO n = 5) was 
used for this purpose (scheme 1).  
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Scheme 1: Schematic diagram of the experimental groups. Timelines display the timing at which each experience was 
performed.  
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3. Intrathecal surgery 
Intrathecal surgeries were performed in the third experimental group, three weeks 
after the first paclitaxel or DMSO injection (group 3; scheme 1) in animals weighing 290-
300 g deeply anesthetized with a mixture of ketamine hydrochloride (0.06 g/kg) and 
medetomidine (0.25 g/kg) delivered via i.p. injections. After confirming total sedation, rats 
were trichotomized with a battery-operated shaver from the area of the ribs to the skull 
and placed in ventral recumbency on top of a styrofoam plate. A midline skin incision 
was made with a scalpel at the level of the T8 vertebra to allow exposure of the bone. 
Muscle and fatty tissue were detached using round tipped scissors. The T8 thoracic 
vertebra region was chosen because this vertebra is the most isolated of all vertebrae 
and therefore the easiest to locate and use as reference. The vertebra bone was cut with 
a fine-tipped rongeur to expose the dura mater which was then carefully perforated with 
an 18-gauge needle parallel to the spinal cord. At this point, a sterilized polyurethane 
catheter (VWR®, France) with a 2.5 cm length was inserted into the intrathecal space 
and moved without resistance towards the lumbar enlargement of the spinal cord using 
fine-tipped forceps (Figure 6-A). This length of the catheter allowed its caudal tip to stand 
proximally to the end of the L3 lumbar segment and beginning of the L4 lumbar segment. 
At the rostral edge of the catheter, a small portion was glued to the intact vertebrae with 
quick glue gel and the muscle around it was sutured. The remaining portion was passed 
subcutaneously to the region of the scapulae. The opened skin around the vertebrae 
was then sutured with surgical staples and the tip of the catheter was externalized in the 
region of the scapulae to prevent the animals from reaching it (Figure 6-B). The catheter 
was filled with 0.9% saline solution and sealed with quick glue gel to prevent 
cerebrospinal fluid leakage. The suture was disinfected with povidone-iodine 
(Betadine®) and the anesthesia was reverted with a subcutaneous injection (s.c.) of 
atipamezole hydrochloride (Revertor® - 0.5 g/kg). The animals were then individually 
housed and monitored daily for body weight and any signs of motor deficit. 
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Figure 6. Catheter implantation into the intrathecal space of the lumbar enlargement of the spinal cord (between L3 and 
L4 lumbar segments). (A) The catheter was inserted at the level of the T8 thoracic vertebra and moved towards the lumbar 
spinal cord. (B) The animals were sutured and the catheter was externalized and sealed at its rostral tip. 
 
 
4. Behavioral evaluation 
 
4.1. Nociceptive behavior 
Nociceptive behavior was assessed using the von Frey and cold plate tests which 
allow to evaluate mechanical and thermal sensitivity, respectively. The tests were 
performed after a period of habituation of one week, during which the animals were 
handled by the experimenter in the test room for 30 minutes and placed in the testing 
apparatus for another 20 minutes every day. The criteria for adequate habituation were 
that animals did not freeze or defecate when placed in the testing apparatus. 
 
To perform the von Frey test, the animals were placed in elevated transparent 
Plexiglas cages with metallic mesh floor (Figure 7-A) and allowed to acclimate to the 
environment for 15-20 minutes before testing. The von Frey test was performed by the 
“up and down” method which consisted on the application of monofilaments, with forces 
ranging from 0.6 g to 60.0 g (Stoelting®, USA), starting with the monofilament 2 g. Each 
filament was consecutively applied to the mid-plantar region of the animal’s paws until it 
bent, for 2-3 seconds. In the absence of a paw withdrawal to a filament, the next higher 
force was delivered whereas in the presence of paw withdrawal, the next lower force was 
delivered. A brisk withdrawal and/or hind paw elevation was recognized as a positive 
response. Two trials were performed for both the left and right hind paws (group 1; 
A B 
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scheme 1) or for the left hind paw (group 3; scheme 1) and each value obtained was 
transformed in logarithm and averaged for each paw.  
 
 
Figure 7. Nociceptive behavior testing apparatuses. (A) Mechanical sensitivity was tested in animals placed in elevated 
Plexiglas cages with metallic mesh floor for application of von Frey monofilaments to the mid-plantar region of the hind 
paws. (B) Thermal sensitivity was tested in animals placed on a cold plate maintained at 0ºC. 
 
 
The von Frey test was used to evaluate the time-course effects of paclitaxel over 
a period of two months (group 1: paclitaxel n = 6; DMSO and saline n = 5 each; scheme 
1) at the following days: before paclitaxel injection (baseline testing) and at 3, 5, 12, 21, 
28, 35, 42, 49 and 56 days after the first injection of paclitaxel (scheme 2).  
 
 
 
 
Scheme 2. Diagram depicting the timing of the experimental procedures performed in group 1 on and von Frey test. CIN 
induction was performed by i.p. injections of paclitaxel (n = 6), DMSO (n = 5) or saline (n = 5) at days 1, 3, 5 and 7 (grey 
box). Von Frey testing was performed at days 0 (baseline), 3, 5, 12, 21, 28, 35, 42, 49 and 56 (VF, orange boxes). 
 
A B 
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The cold plate test was adapted from Jasmin et al. (1998) [86]. During the 
habituation sessions, the animals were placed on the surface of a plate (BIO-CHP 
Hot/Cold Plate Test, Bioseb®, USA/Canada) maintained at 35ºC for 20 minutes. On 
testing days, animals were placed on the surface of the plate that was maintained at 0ºC 
(Figure 7-B) with a cut-off period of 60 s to avoid tissue damage. The time animals spent 
on the cold surface before reacting to the stimulus was recorded and expressed as the 
paw withdrawal latency. A brisk lift or licking of the hind paw was considered a positive 
response. 
 
The von Frey and cold plate tests were used to study the effects of spinal α2A-AR 
activation by the agonist clonidine (group 3; scheme 1). One week after the intrathecal 
surgery, the animals were injected a volume of 10 µl of either clonidine (Sigma-Aldrich®, 
USA) at 1 µg (paclitaxel n = 7; DMSO n = 7), clonidine at 10 µg (paclitaxel n = 6; DMSO 
n = 8) or 0.9% saline (paclitaxel n = 6; DMSO n = 7) through the intrathecal catheter 
using a 50 µl syringe with a 28-gauge needle (Hamilton®, USA). To minimize reflux, the 
same volume of 0.9% saline was immediately injected following clonidine or saline 
injection. The tests were performed before (i.e. baseline) and 15 to 20 minutes after 
clonidine or saline administration. Baseline values of the von Frey test were acquired 
immediately before the injection of clonidine or saline. Baseline values of the cold plate 
test were acquired on the previous day to avoid skin sensitization due to repeated 
exposure to cold. The effects of clonidine were tested at 15 to 20 minutes, which is the 
timing of maximum effect of intrathecal clonidine [87]. After clonidine or saline injection, 
the animals were first tested for mechanical and then cold sensitivity given the noxious 
nature of the cold stimulus which could have biased the response to mechanical 
stimulation [88]. 
 
4.2. Aversive behavior 
The Conditioned Place Preference test is a standard behavioral test used to study 
the rewarding and aversive effects of drugs. This paradigm has been increasingly used 
to investigate the affective (aversive) aspects of pain [89] and it is now admitted that this 
operant paradigm allows the detection of spontaneous (i.e., non-evoked) pain that is 
otherwise difficult to assess in nonverbal animals. The test involves the association of a 
particular environment with a drug treatment through visual and tactile cues 
(conditioning phase). Following the conditioning phase there is a post-conditioning 
phase, during which the animals associate a different environment with the effect of the 
drug but in the absence of the drug. A common variation of this design consists of a 
three-compartment chamber with two different conditioning 
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compartments/contexts, distinguished by visual and sensory cues to which the animal 
is exposed once or several times, that are connected by a neutral compartment, with 
no special characteristics and that is not paired with a drug. Before the conditioning 
phase (i.e. during the pre-conditioning phase), the animal should not present a 
previous preference for any chamber/context. 
 
In this study, we aimed to determine whether paclitaxel induced conditioned-
place aversion (CPA) by pairing this drug to a compartment with specific environmental 
cues. These cues helped the animals associate the compartment where the drug was 
administered to the emotion it elicited when visiting that compartment [27, 28]. The 
second experimental group was used for CPA testing (paclitaxel n = 2; DMSO n = 1; 
scheme 1). The CPA testing apparatus consisted of a 100 x 40 x 40 cm Plexiglas 
chamber divided in three compartments: two 40 x 40 x 40 cm conditioning compartments 
that contained visual and tactile cues and one middle/neutral 20 x 40 x 40 cm 
compartment with no visual or tactile cues. One of the conditioning compartments had a 
floor constituted by 0.5 cm diameter metal rods spaced 2 cm and walls with alternating 
3 cm wide black and white horizontal stripes. The second conditioning compartment had 
a mesh wire floor and walls with alternating 3 cm wide black and white vertical stripes. 
The central/neutral compartment had black Plexiglas walls and floor (Figure 8). Each 
compartment was separated by removable doors.  
Figure 8. CPA testing apparatus (top view). The chamber has two conditioning compartments with distinct visual and 
tactile cues and one neutral compartment with no cues. The cues help animals associate a compartment to the emotion 
elicited by a drug. 
 
The CPA protocol was adapted from Li et al. (2009) [28] and Noda at al. (2014) 
[27], and was conducted as follows. Rats were placed in the neutral chamber, one at a 
time, with full access to all chambers for 15 minutes for 3 consecutive days. Days 1 and 
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2 were used for habituation purposes and on Day 3 (pre-conditioning phase; Scheme 
3), rat’s behavior was video-recorded for 15 minutes and the time spent in each chamber 
was analyzed on EthoLog 2.2. Rats spending less than 20% or more than 80% of the 
entire time in one of the chambers were excluded. Each rat was then randomly assigned 
to a treatment group and a conditioning chamber/environment in a counterbalanced 
fashion. From Days 4 to 11 (conditioning phase; Scheme 3), the animals were allowed 
4 conditioning sessions with paclitaxel (paclitaxel-treated animals n = 2) or DMSO 
(control group; n = 1) on the alternate days 4-6-8-10, during which the animals received 
an i.p. injection of paclitaxel (2.0 mg/kg) or 4% DMSO and were immediately placed into 
their respective assigned conditioning compartment (doors closed) for 1 hour. On days 
5-7-9-11, the animals received an i.p. injection of 0.9% saline and were immediately 
placed into the second/opposite conditioning compartment (doors closed) for 1 hour. We 
performed two post-conditioning sessions (scheme 3), the first on day 12 (the day 
after the last conditioning session), and the second on day 19 (one week after the last 
conditioning session). During both post-conditioning sessions, the rats were placed in 
the neutral chamber in a drug-free state, with access to all chambers, their behavior was 
recorded for 15 minutes and the time spent in each chamber was analyzed on EthoLog 
2.2. The difference between post- and pre-conditioning time spent in each chamber was 
calculated to determine the place preference/aversion score. 
 
 
Scheme 3. Evaluation of the aversive effects of paclitaxel following a conditioning period of four days with the drug. Days 
1 and 2 were used for habituation to the apparatus; day 3 was a pre-conditioning day in which the animals’ behavior was 
filmed. Days 4, 6, 8 and 10 were used for paclitaxel or DMSO administration and days 5, 7, 9 and 11 were used for saline 
administration. Days 12 and 19 were used for evaluation of the place preference/aversion score. 
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5. Vascular perfusion and material processing for 
immunohistochemistry 
All animals, except animals from the experimental group 6, were sacrificed by 
vascular perfusion (scheme 1). Animals from groups 1, 2 and 3 were perfused upon 
completion of behavioral assays. Animals from group 5, upon completing one month 
after CIN induction, were placed on the cold plate surface, which was set at 0ºC, three 
times for 50 seconds each, at an interval of 5 minutes. Then, 2 hours after the first cold 
stimulation, the animals were perfused. The 2-hour interval was required to ensure 
maximal expression of the proto-oncogene c-fos in the spinal dorsal horn after noxious 
stimulation [90, 91]. The vascular perfusion was performed in animals deeply 
anesthetized with 65 mg/kg sodium pentobarbital (Eutasil®) via i.p. injection as follows. 
After confirming sedation by pinching the tail or a hind paw, the animals were placed in 
the supine position and their thorax was opened with scissors to allow access to the 
heart. To prevent blood coagulation, the heart was injected with 0,2 ml of heparin into 
the left ventricle. Then, a nick was inflicted on the left ventricle to allow the insertion of a 
catheter on the way to the ascending aorta for perfusion with 200 ml of calcium-free 
Tyrode's solution followed by 800 ml of fixative solution of 4% paraformaldehyde (PFA) 
in 0,1 M phosphate buffer (pH = 7.2). 
The spinal cords of the animals from the experimental group 3 (implanted with a 
catheter in the intrathecal space) were carefully exposed for verification of the position 
of the catheter. No further processing of the spinal cord was carried out. Only animals 
whose catheter terminated at the spinal L4 segment were included in the analysis. The 
spinal cord of the animals from the experimental groups 1, 2, 4 and 5 were carefully 
exposed, dissected out and immersed in 4% PFA for 4 hours and then cryopreserved, 
at least for 24 hours, in 30% sucrose solution. The spinal L4 and L5 segments were then 
transversally sliced into 3 sets of 30 µm thick sections in a freezing microtome (Leica 
CM1325 microtome, Leica Biosystems® with a Huber Ministat 240 thermostat, Huber®) 
and preserved in a cryoprotectant solution at -20ºC. The spinal lumbar sections from 
groups 1 and 4 were used for immunohistochemical analysis of DBH expression. The L4 
and L5 sections from group 4 were further used for immunhistochemical analysis of α2A-
AR expression and only the L4 sections for immunhistochemical analysis of pCREB. The 
L4 sections from group 5 were used for immunohistochemical analysis of c-Fos 
expression. 
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6. Immunohistochemical studies 
 
6.1. Immunohistochemical detection and analysis of dopamine-β-
hydroxylase (DBH) expression 
 
6.1.1. Immunohistochemical detection 
Immunodetection of DBH was performed using one set of spinal L4 and L5 
sections from the experimental groups 1 (paclitaxel n = 6; DMSO n = 5; saline n = 5) and 
4 (paclitaxel n = 6; DMSO n = 6; saline n = 6), as follows. All transverse sections were 
processed under identical experimental conditions. Free-floating sections were first 
washed with 0.1 M phosphate-buffered saline (PBS) to remove any traces of 
cryoprotectant (four times, 10 minutes each). Then, they were incubated for 15 minutes 
with a 30% hydrogen peroxide solution to block endogenous peroxidase activity, followed 
by a 10-minute permeabilizing step using 0.3% Triton X-100 diluted in PBS (PBS-T). 
Sections were then incubated for 2 hours with a blocking solution of glycine and 10% 
normal horse serum (NHS) diluted in PBS-T to prevent nonspecific binding of the 
antibodies, followed by incubation for one overnight with a mouse-raised anti-DBH 
primary antibody (Millipore®) diluted at 1:5000 in PBS-T and 2% NHS at 4ºC. After 
further washing with PBS-T, the sections were incubated for 1 hour with a horse 
biotinylated anti-mouse secondary antibody (Dako, Agilent Technologies, Denmark) 
diluted at 1:200 in PBS-T and 2% NHS at room temperature. Sections were washed 
before incubation for 1 hour with the Avidin-Biotin Complex (ABC) solution (Vector 
Laboratories). The detection step took place upon incubation with 3,3'-diamino-benzidine 
(DAB, Sigma-Aldrich®, USA). The sections were mounted on gelatine-coated slides, 
cleared in xylol and coverslipped with mounting medium (Eukitt®, Fluka Analytical, 
Germany).  
Photomicrographs were taken from the left and right sides of the spinal dorsal 
horn of each animal. A total of five non-contiguous random sections were acquired under 
the same exposure and lighting settings from a light microscope (Axioskop 40 model, 
Zeiss®, Switzerland) coupled to a high-resolution digital camera (Leica EC3 model) and 
the LAS 4.6.0. software (Leica Microsystems®).  
The quantification of DBH labelling was performed on the ImageJ® software (U. 
S. National Institutes of Health, USA). Before proceeding to the actual quantitative 
analysis, we first optimized the methodology as explained in the next section. 
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6.1.2. Optimization of the methodology to analyze DBH expression 
The optimization procedures described in this section were performed using 
photomicrographs of five L4 sections per animal from the experimental group 1 (scheme 
1).  
A. Selection of the method for image analysis 
In the first step of optimization we aimed at establishing and validating in the lab 
a new method of quantification of immunolabelling in fibers, which is the thresholding 
method [83]. For that, we compared the results yielded by this new method with the 
results obtained by the densitometric analysis of pixels, which has been classically used 
in the lab for the quantification of the expression of proteins both at the cell bodies and 
fibers [92]. 
The densitometric analysis was performed on the superficial spinal dorsal 
laminae (I-II) and the total dorsal laminae (I-VI), which were delimited by using the 
freehand selection tool on ImageJ. The mean intensity of pixels inside each area was 
then measured as follows. Two regions of background staining were selected for 
measuring pixel intensity, one including an area of the dorsal horn without visible fibers 
(A) and the other from the glass of the slide (B). The DBH fiber density within laminae I-
II and I-VI was determined by subtracting the mean intensity of pixels in background A 
to the mean intensity of pixels in the total area and by normalizing it with the 
corresponding value for background B.  
The thresholding analysis was performed by selecting a small random area of 
background staining using the freehand selection tool on ImageJ and measuring its 
intensity statistics. Mean and standard deviation (SD) values of the background staining 
were obtained. Images were then converted to an 8-bit grayscale. The threshold level 
for DBH positive pixels was determined by setting a value of 5 SDs above the mean light 
background level, as follows: Threshold level (rounded to units) = mean background 
value – (5 x SD). The regions of interest (ROI) for this analysis, which comprised the 
superficial (laminae I-II) and the total (laminae I to VI) regions of the dorsal horn, were 
delimited manually for each image using the freehand selection tool and saved in the 
ROI Manager tool. The percentage of DBH positive pixels inside the ROIs was 
automatically calculated by the ImageJ software. 
 
B. Delineation of the region of analysis  
In the second step of optimization, we aimed at determining whether a fixed area, 
measuring 228 x 112 µm and positioned along the spinal dorsal horn at the same location 
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in each section encompassing a portion of laminae I, II, III, IV and V (Figure 9), could be 
a representative sampling of the spinal dorsal horn labelling. For that, we compared the 
results obtained by this method of delineation with the density of DBH labelling in the 
total area of laminae I-VI manually delimited with the freehand tool. We performed this 
analysis using the thresholding method, which was selected from the first step of 
optimization, to measure the percentage of DBH positive pixels inside the ROIs, as 
explained above. 
 
 
Figure 9. Thresholding analysis for determination of the percentage of DBH positive pixels inside a 228 x 112 µm rectangle 
using ImageJ software. The ROI (yellow rectangle) was positioned along the spinal dorsal horn encompassing a portion 
of laminae I, II, III, IV and V. The percentage of DBH positive pixels inside this ROI was automatically calculated by ImageJ 
software (green box). 
 
 
6.1.3. Analysis of DBH expression 
The thresholding method was selected for image analysis and the density of DBH 
labelling was quantified by using the 228 x 112 µm fixed rectangle as the ROI. The ROI 
was thoroughly positioned in the same region of the dorsal horn of each section to 
minimize variance. DBH labelling was analyzed in five random non-contiguous L4 and 
five random non-contiguous L5 sections per animal from the experimental groups 1 and 
4 (scheme 1).  
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6.2. Immunohistochemical detection and analysis of pCREB expression 
The analysis of pCREB expression was performed using one set of spinal L4 and 
L5 sections from the experimental group 4 (paclitaxel n = 6; DMSO n = 6; saline n = 6; 
scheme 1), immunoreacted as follows. All transverse sections were processed under 
identical experimental conditions. Free-floating sections were first washed with 0.1 M 
PBS to remove any traces of cryoprotectant (four times for 10 minutes). Then, they were 
incubated for 15 minutes with a 30% hydrogen peroxide solution to block endogenous 
peroxidase activity, followed by a 10-minute permeabilizing step using PBS-T. Sections 
were then incubated for 2 hours with a blocking solution of glycine and 10% normal goat 
serum (NGS) diluted in PBS-T to prevent nonspecific binding of the antibodies, followed 
by incubation for two overnights with a rabbit-raised anti-pCREB primary antibody 
(Millipore®) diluted at 1:5000 in PBS-T and 2% NGS at 4ºC. After further washing with 
PBS-T, the sections were incubated for 1 hour with a swine biotinylated anti-rabbit 
secondary antibody (Dako, Agilent Technologies, Denmark) diluted at 1:200 in PBS-T 
and 2% NGS at room temperature. Sections were washed before incubation for 1 hour 
with the Avidin-Biotin Complex (ABC) solution (Vector Laboratories). The detection step 
took place upon incubation with 3,3'-diamino-benzidine (DAB, Sigma-Aldrich®, USA). 
The sections were mounted on gelatine-coated slides, cleared in xylol and coverslipped 
with mounting medium (Eukitt®, Fluka Analytical, Germany).  
Photomicrographs were taken from the left and right sides of the spinal dorsal 
horn of each animal. A total of six random non-contiguous L4 and six random non-
contiguous L5 sections were acquired under the same exposure and lighting settings 
from a light microscope (Axioskop 40 model, Zeiss®, Switzerland) coupled to a high-
resolution digital camera (Leica EC3 model) and the LAS 4.6.0. software (Leica 
Microsystems®). 
The quantification of pCREB-immunoreactive (IR) nuclei was performed on the 
ImageJ® software (U. S. National Institutes of Health, USA) using an adaptation of the 
thresholding analysis, as follows. Images were first converted to an 8-bit grayscale and 
the threshold level for pCREB-IR positive pixels was automatically determined by 
ImageJ. Images were then converted into binary images and labelling appeared as black 
particles. The particles were segmented using the Watershed tool to separate 
overlapping particles. The number of particles was then calculated by ImageJ on four 
different ROIs: the superficial laminae I-II, lamina III, IV and V of the spinal dorsal horn, 
carefully delimited by superimposing a digital diagram of the L4 segment taken from the 
atlas of the rat’s brain by Paxinos & Watson [93] on each section of the spinal cord. 
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6.3.  Immunohistochemical detection and analysis of c-Fos expression 
The analysis of c-Fos expression was performed using one set of spinal L4 
sections from the experimental group 5 (paclitaxel n = 3; DMSO n = 4; scheme 1). We 
only immunoreacted the L4 segment as this is the main spinal segment receiving noxious 
sensory inputs from the hind paws [94]. The sections were immunoreacted as follows. 
All transverse sections were processed under identical experimental conditions. Free-
floating sections were first washed with 0.1 M PBS to remove any traces of 
cryoprotectant (four times for 10 minutes). Then, they were incubated for 20 minutes with 
a 30% hydrogen peroxide solution to block endogenous peroxidase activity, followed by 
a 10-minute permeabilizing step using PBS-T. Sections were then incubated for 2 hours 
with a blocking solution of glycine and 10% normal swine serum (NSS) diluted in PBS-T 
to prevent nonspecific binding of the antibodies, followed by incubation for two overnights 
with a rabbit-raised anti-c-Fos primary antibody (Oncogene®) diluted at 1:2500 in PBS-
T and 2% NSS at 4ºC. After further washing with PBS-T, the sections were incubated for 
1 hour with a swine biotinylated anti-rabbit secondary antibody (Dako, Denmark) diluted 
at 1:200 in PBS-T and 2% NSS at room temperature. Sections were again washed 
before incubation for 1 hour with the Avidin-Biotin Complex (ABC) solution (Vector 
Laboratories). The detection step took place upon incubation with 3,3'-diamino-benzidine 
(DAB, Sigma-Aldrich®, USA). The sections were mounted on gelatine-coated slides, 
cleared in xylol and coverslipped with mounting medium (Eukitt®, Fluka Analytical, 
Germany).  
Photomicrographs were taken from the left and right sides of the spinal dorsal 
horn of each animal. A total of seven random non-contiguous L4 sections were acquired 
under the same exposure and lighting settings from a light microscope (Axioskop 40 
model, Zeiss®, Switzerland) coupled to a high-resolution digital camera (Leica EC3 
model) and the LAS 4.6.0. software (Leica Microsystems®).  
The quantification of c-Fos-IR nuclei was performed on the ImageJ® software (U. 
S. National Institutes of Health, USA). The Cell Counter tool was used to manually count 
the number of c-Fos-IR nuclei on lamina I-II, lamina III, lamina IV and lamina V of the 
spinal dorsal horn. The spinal laminae were carefully delimited by superimposing a digital 
diagram of the L4 segment taken from the atlas of the rat’s brain by Paxinos & Watson 
[93] on each section of the spinal cord. 
 
6.4.  Immunohistochemical detection and analysis of α2A-AR expression 
The analysis of α2A-AR expression was performed using one set of spinal L4 and 
L5 sections from the experimental group 4 (paclitaxel n = 6; DMSO n = 6; saline n = 6; 
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scheme 1), immunoreacted as follows. All transverse sections were processed under 
identical experimental conditions. Free-floating sections were washed with 0.1 M PBS to 
remove any traces of cryoprotectant (four times for 10 minutes). Then, they were 
incubated for 30 minutes with a incubated with a 1% sodium borohydride solution to 
reduce the tissue autofluorescence, followed by a 10-minute permeabilizing step using 
PBS-T. Sections were then incubated for 2 hours with blocking solution of glycine and 
10% normal horse serum (NHS) diluted in PBS-T to prevent nonspecific binding of the 
antibodies, followed by incubation for two overnights with a rabbit-raised anti-α2A primary 
antibody (Neuromics®) diluted at 1:500 in PBS-T and 2% NHS at 4ºC. After further 
washing with PBS-T, the sections were incubated for 1 hour with a donkey anti-rabbit 
Alexa 488 (Molecular Probes®) diluted at 1:1000 in PBS-T. The sections were mounted 
on gelatine-coated slides, coverslipped with glycerol–phosphate buffer 0.4 M (3:1). 
Photomicrographs were taken from the left and right sides of the spinal dorsal 
horn of each animal. A total of five random non-contiguous L4 and five random non-
contiguous L5 sections were acquired under the same time exposure and laser light 
wavelength (488 nm) on an ApoTome Slider (Zeiss®) fluorescence microscope coupled 
to the AxioVision Rel. 4.8. software (Zeiss®).  
The quantification of α2A-AR was performed on the ImageJ® software (U. S. 
National Institutes of Health, USA) using a thresholding analysis as explained above, but 
with small alterations as the method was now applied to fluorescence staining. Mean 
and SD values of background staining were obtained. Images already in the 16-bit 
grayscale format were thresholded. The threshold level for α2A-AR positive pixels was 
determined by setting a value of 5 SDs above the mean dark background level on the 
threshold tool, as follows: Threshold level (rounded to units) = mean background value 
+ (5 x SD). The α2A-AR labelling appeared as white in a dark background, which explains 
why we added the value of 5 standard deviations to the mean background staining 
instead of subtracting it as in DBH expression analysis. The ROI was the superficial 
laminae I-II which was manually drawn for each image using the freehand selection tool. 
The percentage of α2A-AR positive pixels inside the ROI was automatically calculated by 
the ImageJ software. 
 
 
7. Western blotting analysis of α2A-AR expression 
Western blotting analysis of α2A-AR expression was performed using lumbar 
spinal cord sections of experimental group 6 (paclitaxel n = 5; DMSO n = 5; scheme 1), 
harvested at one month after CIN induction, as follows. Animals were deeply 
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anesthetized with an overdose of 65 mg/kg sodium pentobarbital via i.p. injection and 
sacrificed by decapitation. A portion of the lumbar spinal cord containing the L4 and L5 
segments was harvested and the left and right spinal cord were separated. Each hemi-
section was further dissected to separate the dorsal and ventral horn and the biological 
material was immediately stored at -80ºC. 
The expression of α2A-AR was studied in the dorsal portion of the L4 and L5 
segments. For that, the tissues were homogenized in lysis buffer (TBS-T: 20 mM Tris 
HCl pH 7.4; 150 mM NaCl; 0.1% Triton X-100) containing phosphatase inhibitor cocktail 
2 (sodium orthovanadate, sodium molybdate, sodium tartrate and imidazole) and 3 
(cantharidin, (-)--bromolevamisole oxalate and calyculin A; Sigma-Aldrich®, USA) and 
protease inhibitor ([4-(2-aminoethyl) benzenesulfonyl fluoride hydrochloride], aprotinin, 
bestatin hydrochloride, -[N-(trans-epoxysuccinyl)-L-leucine 4-guanidinobutylamide], 
leupeptin, hemisulfate salt and pepstatin A; Sigma-Aldrich®, USA) using a MagNA 
Lyser® (Roche, Switzerland). The total protein concentration was quantified by the 
Bradford method using Bovine Serum Albumin (BSA) protein as a standard. A total of 20 
g of protein was denatured at 60C for 10 minutes and centrifuged at 14800 rpm for 2 
minutes in the 1x GLB (1.875 M Tris pH8.8; 15% glicerol; 6% SDS; 0.1% - 0.05% 
Bromophenol Blue) containing 100 mM Dithiothreitol (DTT). Samples were loaded and 
electrophoresed on 12% SDS-PAGE at 200 V and 32 mA. Pre-stained molecular weight 
marker (NZY Colour Protein Marker II®, NZYTech, Portugal) was simultaneously loaded 
to monitor electrophoresis and identify molecular weights. The proteins were then 
electroblotted onto nitrocelulose membranes by Trans-Blot® Turbo™ (BioRad, USA). 
After several washes with TBS-T, the membrane was blocked with 5% of Blotting-Grade 
Blocker (Bio-Rad, USA) in TBS-T for 1 hour at room temperature and then incubated 
with the primary antibodies, rabbit anti-2AARs (1:1000, Neuromics, USA) in TBS-T 
containing 5% of Blotting-Grade Blocker (Bio-Rad, USA) for 24 hours at 4C. Membranes 
were then washed and incubated in anti-rabbit secondary antibodies conjugated to 
horseradish peroxidase (HRP, 1:10000, Jackson Immunoresearch Europe, UK) in TBS-
T with 5% of Blotting-Grade Blocker for 1 hour. After 2 washes in TBS-T, the membranes 
were incubated with Clarity Western ECL Substrate (Bio-Rad, USA), a 
chemiluminescence reagent, for 5 minutes and immunoreative bands were detected by 
Chemidoc system (Bio-Rad, USA). Semi-quantification of bands was performed using 
Image Lab software (Bio-Rad, USA) and expressed in arbitrary units. 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as loading 
protein internal control, with the membranes being incubated with mouse anti-GAPDH 
(1:10000, Abcam, UK) followed by incubation in anti-mouse secondary antibody 
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conjugated to HRP (1:10000, Jackson Immunoresearch Europe, UK). Detection and 
quantification of GAPDH immunoreactive bands were performed as described above. 
The results of the quantification of α2A-AR expression were presented as normalized for 
GAPDH.  
 
 
8. Statistical analysis 
The behavioral data obtained in the von Frey and cold plate tests were analyzed 
by two-way repeated measures ANOVA followed by Tukey’s post-hoc test for multiple 
comparisons when applied. The behavioral data collected in the CPA test was not 
statistically analyzed because only three (two paclitaxel-treated and one control/DMSO-
treated) animals were used and this was a preliminary study. Data obtained in the 
histochemical analysis of pCREB and c-Fos was analyzed by two-way ANOVA followed 
by Tukey’s test for multiple comparisons when applied. Data obtained in the 
histochemical analysis of DBH and α2A-AR expression was analyzed by one-way ANOVA 
followed by Tukey’s test for multiple comparisons when appropriate. Data obtained in the 
western blot analysis of α2A-AR expression was compared by unpaired student t-test. 
Statistical analysis was performed by GraphPad Prism version 6.00 (GraphPad 
Software, USA). Significance level was set at 0.05. 
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Results 
 
1. Behavioral characterization of paclitaxel-induced neuropathy 
 
1.1. Nociceptive behavior 
The effects of paclitaxel on pain behavior were assessed by the von Frey test 
prior to and at 3, 5, 12, 21, 28, 35, 42, 49 and 56 days following the first paclitaxel injection 
(scheme 2). Paw withdrawal thresholds from each animal at each time tested were 
determined both from the left and right hind paws. No significant differences were found 
between the left and right paw withdrawals (F1,10 = 0.328; p = 0.579). Paw withdrawal 
thresholds from each animal of this experimental group were then determined as the 
average of the left and rights hind paws (Figure 10). 
 Overall, the analysis of the data revealed a significant effect of the treatment (F2, 
13 = 63.36, p < 0.0001), time (F9, 117 = 3.747, p = 0.0004) and interaction (treatment x 
time): F18, 117 = 4.869, p < 0.0001. Paclitaxel-treated animals differed significantly from 
both DMSO- (p < 0.0001) and saline-treated (p < 0.0001) animals. DMSO- and saline-
treated animals were not significantly different (p > 0.9999). The time course analysis 
revealed that at baseline (i.e. before the first injection of paclitaxel), no significant 
differences were observed between the groups. Paclitaxel-treated animals showed 
significant lower paw withdrawal thresholds compared to baseline at days 5, 12, 21, 42, 
49 and 56 and also compared both to DMSO- and saline-treated animals from D5 to D56 
(Figure 10).  
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Figure 10. Time course effects of systemic paclitaxel administration on mechanical sensitivity assessed by the von Frey 
test. The test was performed before i.e. at baseline (BL) and several days (D) after the first injection of paclitaxel. Data 
are presented as mean ± SEM (paclitaxel n = 6; DMSO and saline n = 5 each group). +p < 0.05; ++p < 0.01; +++p < 0.001 
vs baseline; #p < 0.05; ##p < 0.01; ###p < 0.001 vs saline; *p < 0.05; **p < 0.01; ***p < 0.001 vs DMSO. 
 
1.2. Aversive behavior 
The aversive behavior was studied using the CPA test. The animals were 
conditioned with either paclitaxel and saline (n = 2) or DMSO and saline (n = 1). Two 
post-conditioning sessions were conducted, the first which took place the day after the 
last conditioning session (post-conditioning 1) and the second which took place a week 
after the last conditioning session (post-conditioning 2). Paclitaxel-treated animals spent 
less time in the compartment paired with paclitaxel compared to pre-conditioning either 
at the first (difference score: -211,34 ± 75,185 s; Figure 11-A) and second (difference 
score: -284,015 ± 97,15 s; Figure 11-A) post-conditioning sessions. The animals spent 
almost the same amount of time in the compartment paired with saline compared to pre-
conditioning either at the first (15,945 ± 197,365 s; Figure 11-A) and second (difference 
score: 60,875 ± 211,645 s; Figure 11-A) post-conditioning sessions. The control animal 
(DMSO-treated) also spent less time in the DMSO-paired compartment at the first 
(difference score: -236,23 s; Figure 11-B) and second (difference score: -171,64 s) post-
conditioning sessions. The DMSO-conditioned rat spent more time in the saline-paired 
compartment at the first (difference score: 203,915 s; Figure 11-B) and second 
(difference score: 231,145 s; Figure 11-B) post-conditioning sessions. 
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Figure 11. Conditioned place aversion evaluated by the CPA test. The animals were conditioned in two different 
compartments with paclitaxel and saline (A), respectively, or DMSO and saline (B), respectively. The time spent in each 
compartment was evaluated before (pre-conditioning) and after (post-conditioning) the conditioning sessions and the 
difference between the two sessions was determined. Two post-conditioning sessions were conducted: one following the 
last conditioning session (post-conditioning 1), and the second, a week after the last conditioning session (post-
conditioning 2). Data are presented as mean of the difference ± SEM (paclitaxel/saline n = 2; DMSO/saline n = 1). 
 
 
2. Effects of paclitaxel on spinal neuronal activation 
 
2.1. Expression of pCREB 
The expression of pCREB was studied at the spinal lumbar L4 dorsal horn of 
saline- (n = 6, Figure 12-A), DMSO- (n = 6; Figure 12-B) and paclitaxel-treated (n = 6; 
Figure 12-C) animals at one month after CIN induction without any further manipulation 
before vascular perfusion. The overall analysis revealed a main effect of treatment (F2, 
60 = 11.57, p < 0.0001) and a main effect of dorsal horn laminae (F3, 60 = 78.70, p < 
0.0001), but no interaction (treatment x dorsal horn laminae: F6, 60 = 0.05809, p = 0.9992). 
Overall, regardless of the dorsal horn laminae, saline-treated animals presented a higher 
number of pCREB-IR nuclei compared to DMSO- (p = 0.0002; Figure 12-D) and 
paclitaxel-treated (p = 0.0005; Figure 12-D) animals. No differences were found between 
DMSO- and paclitaxel-treated animals (p = 0.9499; Figure 12-D). Regardless of the 
treatment, the total number of pCREB-IR nuclei was significantly higher in laminae I-II 
compared to lamina III, lamina IV and lamina V (p < 0.0001 for each comparison; Figure 
12-D). 
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Figure 12. Expression of pCREB in the spinal dorsal horn at one month after CIN induction. Representative 
photomicrographs show pCREB immunoreactivity in the spinal dorsal horn of saline- (A), DMSO- (B) and paclitaxel-
treated (C) animals. Scale bar in A: 200 µm. All images were acquired under the same magnification. The number of 
pCREB-IR nuclei was evaluated in dorsal horn laminae I-II, III, IV and V (D). Data are presented as mean ± SEM 
(paclitaxel, DMSO and saline n = 6 each group). 
 
2.2. Cold-induced c-Fos expression 
The expression of c-Fos was studied at the spinal lumbar L4 dorsal horn of 
DMSO- (n = 4; Figure 13-A) and paclitaxel-treated (n = 3; Figure 13-B) animals, at one 
month after CIN induction. Two hours before vascular perfusion the animals were 
submitted to noxious-cold stimulation.  
Overall, cold stimulation induced a higher number of c-Fos-IR nuclei in paclitaxel-
treated animals (F1, 20 = 9.158, p = 0.0067). The overall analysis also revealed a main 
effect of dorsal horn laminae (F3, 20 = 4.955, p = 0.0099), but no interaction (treatment x 
dorsal horn laminae: F3, 20 = 0.8410, p = 0.4874). Regardless of the treatment, the 
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number of c-Fos-IR nuclei was significantly higher in lamina III compared to laminae I-II 
(p = 0.0373; Figure 13-C) and to lamina IV (p = 0.0160; Figure 13-C).  
 
 
Figure 13. Expression of c-Fos after moxious-cold stimulation in the spinal dorsal horn at one month after CIN induction. 
Representative photomicrographs of c-Fos immunoreactivity in the spinal dorsal horn of DMSO- (A) and paclitaxel-treated 
(B) animals. Scale bar in A: 200 µm. Both images were acquired under the same magnification. The total number of c-
Fos-IR nuclei was evaluated in dorsal horn laminae I-II, III, IV and V (C). Data are presented as mean ± SEM (paclitaxel 
n = 3; DMSO n = 4). 
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3. Study of descending noradrenergic modulation in the 
paclitaxel-induced model of neuropathy 
 
3.1. Analysis of DBH expression 
 
3.1.1. Optimization of the methodology to analyze DBH expression  
The optimization of the methodology to quantify DBH labelling was conducted on 
spinal lumbar L4 sections of the two-months experimental group (group 1, scheme 1) 
treated with paclitaxel (n = 6), DMSO (n = 5) and saline (n = 5). 
 
A. Selection of the method of image analysis 
Densitometric (Figure 14-A, B) and thresholding (Figure 14-C, D) methods of 
image analysis were compared using the same spinal cord sections and areas (dorsal 
horn superficial laminae I-II – Figure 14-A, C – and laminae I-VI – Figure 14-B, D). We 
found the same trend of quantification by both methods of analysis, that is, no differences 
in DBH labelling between the groups in the superficial dorsal horn laminae (densitometric 
analysis: F2, 11 = 2.486, p = 0.1286; thresholding analysis: F2, 11 = 2.120, p = 0.1664; 
Figure 14-A, C) and in the entire dorsal horn area (densitometric analysis: F2, 11 = 1.052, 
p = 0.3819; thresholding analysis: F2, 11 = 0.8655, p = 0.4476; Figure 14-B, D). The 
thresholding method yielded the same results as the classic densitometric analysis, 
which then validated the thresholding method as a reliable tool of analysis for use in the 
subsequent analysis. 
 
B. Delineation of the region of analysis 
The thresholding method was used for optimization of the delineation of the 
region/area for DBH labelling analysis in the spinal dorsal horn. We compared the total 
dorsal horn area (laminae I-VI) delimited manually to a fixed rectangular area (228 x 112 
µm) placed in the center of the dorsal horn as to include laminae I to V. We found the 
same trend of quantification when analyzing both areas, that is, no differences in DBH 
labelling between the groups in the manually delimited dorsal horn (F2, 11 = 0.8655, p = 
0.4476; Figure 15-A) and when analyzing the fixed area (F2, 11 = 0.3048, p = 0.7433; 
Figure 15-B). 
Since the fixed rectangular area encompassing most of the dorsal horn yielded 
the same results as the manually delimited area, we selected the fixed area for 
subsequent analysis. 
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Figure 14. Optimization of the methodology to quantify DBH expression. DBH expression was quantified by a 
densitometric (A, B) and thresholding (C, D) methods in the superficial laminae I-II (A, C) and in laminae I-VI (B, D) of the 
spinal dorsal horn. Data are presented as mean ± SEM (paclitaxel n = 6; saline and DMSO n = 5 each group). 
 
 
 
Figure 15. Optimization of the area for analysis of DBH expression. DBH expression was quantified in a manually delimited 
area (A) and in a fixed area (B) of the spinal dorsal horn. Data are presented as mean ± SEM (paclitaxel n = 6; saline and 
DMSO n = 5 each group). 
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3.1.2. Effects of paclitaxel on DBH expression 
The effects of paclitaxel treatment on the expression of DBH in the spinal cord 
were studied in spinal L4 and L5 sections of the one-month experimental group (group 
4: paclitaxel n = 6; DMSO n = 6; saline n = 6; scheme 1) and the two-months experimental 
group (group 1: paclitaxel n = 6; DMSO n = 5; saline n = 5; scheme 1). 
At one month after CIN induction (Figure 16), the overall data analysis showed 
that there were differences between the three groups analyzed at the spinal L4 segment 
(F2, 15 = 3.662, p = 0.0500; Figure 16-A-C, G) but not at the L5 segment (F2, 15 = 3.245, p 
= 0.0674; Figure 16-D-F, H). In L4 sections, paclitaxel-treated animals showed a higher 
percentage of DBH positive pixels when compared to DMSO-treated (p = 0.0495) 
animals (Figure 16-G). No significant differences were observed between L4 sections of 
DMSO- and saline-treated animals. 
At two months after CIN induction (Figure 17), the data analysis revealed no 
significant differences between the three groups of animals both at the spinal L4 (F2, 11 = 
0.3048, p = 0.7433; Figure 17-A-C, G) and L5 (F2, 12 = 2.376, p = 0.1351; Figure 17-D-F, 
H) segments. 
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Figure 16. Expression of DBH in the spinal dorsal horn at one month after CIN induction. Representative 
photomicrographs of DBH immunoreactivity in the spinal L4 (A, B, C) and L5 (D, E, F) segments of saline- (A, D), DMSO- 
(B, E) and paclitaxel-treated (C, F) animals. Scale bar in A and D: 200 µm. All images were acquired under the same 
magnification. The percentage of DBH positive pixels was determined from a fixed area at the lumbar dorsal horns (G, 
H). Data are presented as mean ± SEM (paclitaxel, DMSO and saline n = 6 for each group). *p < 0.05 vs DMSO. 
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Figure 17. Expression of DBH in the spinal dorsal horn at two months after CIN induction. Representative 
photomicrographs of DBH immunoreactivity in the spinal L4 (A, B, C) and L5 (D, E, F) segments of saline- (A, D), DMSO- 
(B, E) and paclitaxel-treated (C, F) animals. Scale bar in A and D: 200 µm. All images were acquired under the same 
magnification. The percentage of DBH positive pixels was determined from a fixed area at the lumbar dorsal horns (G, 
H). Data are presented as mean ± SEM (paclitaxel n = 6; saline and DMSO n = 5 each group). 
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3.2. Analysis of spinal α2A-AR expression 
The expression of α2A-AR at the spinal dorsal horn were analyzed in spinal L4 
and L5 sections by immunofluorescence (paclitaxel n = 6; DMSO n = 6; saline n = 6; 
Figure 18) and western blotting (paclitaxel n = 5; DMSO n = 5; Figure 19) at one month 
after CIN induction. The immunofluorescence analysis revealed a significant difference 
between the three groups in the L5 segment (F2, 13 = 5.727, p = 0.0165; Figure 18-D-F, 
H) but no differences in the L4 segment (F2, 13 = 1.656, p = 0.2287; Figure 18-A-C, G). In 
the L5 segment, the percentage of α2A-AR positive pixels was significantly less abundant 
in paclitaxel- compared to saline-treated animals (p = 0.0130, Figure 18-D, H). No 
significant differences were observed between DMSO- and paclitaxel-treated animals (p 
= 0.3351) and between DMSO- and saline-treated animals (p = 0.1408; Figure 18-D-F, 
H). 
The western blotting analysis showed that the expression of α2A-AR remained 
unaltered between paclitaxel- and DMSO-treated animals (F4, 4 = 1.214, p = 0.8553; 
Figure 19). 
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Figure 18. Expression of α2A-AR at the spinal dorsal horn at one month after CIN induction. Representative fluorescence 
photomicrographs of α2A-AR immunoreactivity in the spinal L4 (A, B, C) and L5 (D, E, F) sections of saline- (A, D), DMSO- 
(B, E) and paclitaxel-treated (C, F) animals. White scale bar in A and D: 50 µm. All images were acquired under the same 
magnification. The percentage of α2A-AR positive pixels was determined in the laminae I-II. Data are presented as mean 
± SEM (paclitaxel, DMSO and saline n = 6 each group). +p < 0.05 vs saline. 
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Figure 19. Expression of α2A-AR in the dorsal portion of the lumbar spinal cord (L4-L5) at one month after CIN induction. 
Graph A shows the densitometric quantification of α2A-AR of the blots (B) from DMSO- and paclitaxel-treated animals. 
GAPDH was used as a control of the western blotting procedure. Data are presented as mean ± SEM (paclitaxel and 
DMSO n = 5 each group). 
 
3.3. Analysis of spinal α2A-AR function 
Functional analysis of spinal α2A-AR was performed upon intrathecal 
administration of the α2A-AR agonist clonidine in DMSO- (n = 22) and paclitaxel-treated 
(n = 19) animals at one month after CIN induction. The behavioral effects of clonidine at 
1 µg and 10 µg were tested on the von Frey (Figure 20-A-C) and cold plate (Figure 20-
D-F) tests.  
In the von Frey test, the paw withdrawal thresholds were determined from the left 
hind paw. We determined paw withdrawals only from one paw as the mechanical 
sensitivity did not differ significantly between left and right paws after CIN induction 
(section 1.1.). The analysis of the effects of clonidine in paclitaxel-treated animals (Figure 
20-B) also revealed a main effect of treatment (F2, 16 = 8.423, p = 0.0032), time (F1, 16 = 
86.15, p < 0.0001) and interaction (treatment x time: F2, 16 = 18.27, p < 0.0001). Both 
doses of clonidine induced a significant increase of paw withdrawal thresholds compared 
to baseline (clonidine at 1 µg: p < 0.0001; clonidine at 10 µg: p < 0.0001) and saline 
(clonidine at 1 µg: p = 0.0008; clonidine at 10 µg: p < 0.0001). There were no differences 
between clonidine at 1 µg and 10 µg (p = 0.2525). At baseline, paw withdrawal thresholds 
were not significantly different between the different groups (Figure 20-B). The injection 
of saline did not induce any significant effects (Figure 20-B). The analysis of the effects 
of clonidine in DMSO-treated animals (Figure 20-A) revealed a main effect of treatment 
(F2, 19 = 7.684, p = 0.0036), time (F1, 19 = 27.96, p < 0.0001) and interaction (treatment x 
time: F2, 19 = 7.471, p = 0.0040). Both doses of clonidine induced a significant increase 
of paw withdrawal thresholds compared to baseline, i.e. before clonidine injection 
(clonidine at 1 µg: p = 0.0070; clonidine at 10 µg: p = 0.0028), and saline (clonidine at 1 
GAPDH 
α2A-AR 
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A B 
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µg: p = 0.0010; clonidine at 10 µg: p = 0.0002). There were no differences between 
clonidine at 1 µg and 10 µg (p = 0.9985). At baseline, paw withdrawal thresholds were 
not significantly different between the different groups (Figure 20-A). The injection of 
saline did not induce any significant effects (Figure 20-A). The analysis of the percentage 
of change induced by clonidine indicated that paclitaxel induced a higher percentage of 
change in paw withdrawal thresholds both at clonidine doses of 1 µg (p = 0.0177; Figure 
20-C) and 10 µg (p = 0.0033; Figure 20-C) compared to DMSO. 
 
 
In the cold plate test, the analysis of the effects of clonidine in paclitaxel-treated 
animals (Figure 20-E) revealed a main effect of treatment (F2, 16 = 9.777, p = 0.0017), 
time (F1, 16 = 50.38, p < 0.0001) and interaction (treatment x time: F2, 16 = 11.41, p = 
0.0008). Both doses of clonidine induced a significant increase of paw withdrawal latency 
compared to baseline (clonidine at 1 µg: p = 0.0005; clonidine at 10 µg: p < 0.0001) and 
saline (clonidine at 1 µg: p = 0.0015; clonidine at 10 µg: p < 0.0001). There were no 
differences between clonidine at 1 µg and 10 µg (p = 0.2594). At baseline, paw 
withdrawal thresholds were not significantly different beween the different groups (Figure 
20-E). The injection of saline did not induce any significant effects (Figure 20-E). The 
analysis of the effects of clonidine in DMSO-treated animals (Figure 20-D) revealed a 
main effect of treatment (F2, 19 = 14.83, p = 0.0001), time (F1, 19 = 86.54, p < 0.0001) and 
interaction (treatment x time: F2, 19 = 24.16, p < 0.0001). Both doses of clonidine induced 
a significant increase of paw withdrawal latency compared to baseline (clonidine at 1 µg: 
p = 0.0028; clonidine at 10 µg: p < 0.0001) and to saline (clonidine at 1 µg: p < 0.0001; 
clonidine at 10 µg: p < 0.0001). There were no differences between clonidine at 1 µg and 
10 µg (p = 0.9334). At baseline, paw withdrawal latency was not significantly different 
between the different groups (Figure 20-D). The injection of saline did not induce any 
significant effects (Figure 20-D). The analysis of the percentage of change induced by 
clonidine showed that paclitaxel induced only a significant higher percentage of change 
in paw withdrawal latency at clonidine dose of 10 µg (p = 0.0447; Figure 20-F) compared 
to DMSO. 
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Figure 20. Effects of intrathecal administration of clonidine in the von Frey (A-C) and the cold plate (D-F) tests. Graphs A 
and B show paw withdrawal thresholds 15-20 minutes after clonidine administration for the von Frey test. Graphs D and 
E show paw withdrawal latencies 30 minutes after clonidine administration for the cold plate test. Dashed lines represent 
mean baseline values (BL) for DMSO- and paclitaxel-treated animals. Graphs C and F show the percentage of change 
from baseline of paw withdrawal thresholds and latencies, respectively, at clonidine doses of 1 and 10 µg. Data are 
presented as mean ± SEM (clonidine at 1 µg: paclitaxel n = 7; DMSO n = 7; clonidine at 10 µg: paclitaxel n = 6; DMSO n 
= 8; saline: paclitaxel n = 6; DMSO n = 7). **p < 0.01; ***p < 0.001 vs baseline; ##p < 0.01; ###p < 0.001 vs saline; +p < 
0.05; ++p < 0.01 vs DMSO.  
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Discussion 
 
The use of a rat model in the current study enabled us to study how systemically 
administered paclitaxel affects the central nervous system. The main results gathered in 
this thesis established that paclitaxel-treated animals developed and maintained 
mechanical sensitivity for at least two months after the beginning of the treatment. Our 
preliminary behavioral data suggest that paclitaxel also engages the affective component 
of pain. The alterations in pain behavior are paralleled at the molecular level by an 
increase in the expression of c-Fos, a marker for the activation of nociceptive neurons, 
in the spinal dorsal horn after noxious cold stimulation. Finally, paclitaxel treatment also 
led to increased expression of the noradrenaline biosynthetic enzyme DBH in the spinal 
cord and a potentiation of the inhibitory function of spinal α2-AR. These results suggest 
a recruitment of descending noradrenergic inhibition probably to remediate increased 
central sensitization.  
 
1. Behavioral alterations during CIN 
 
The nociceptive behavioral testing showed that paclitaxel-treated animals 
developed significant mechanical sensitivity a few days after initiation of the treatment. 
The development of mechanical sensitivity has been reported in several other studies 
which used, as in our study, a low-dose regimen of paclitaxel [71, 74, 95]. In our study, 
mechanical allodynia was detected from day 5 onwards, however some studies have 
reported that mechanical sensitivity can appear earlier during a so-called acute painful 
phase [95]. Indeed, Yan et al. (2015) [96] detected lower paw withdrawal thresholds in 
response to mechanical stimulation as soon as 2h after a single intravenous injection of 
paclitaxel at the same dose we used in our study. Dina et al. (2001) [97] reported the 
same behavior between 1 to 6h after an intraperitoneal injection of paclitaxel at a smaller 
dose. Our time course study also showed that mechanical allodynia was maintained for 
at least two months after CIN induction, which confirms the long-lasting chronic effects 
of paclitaxel treatment previously seen by others [71, 74]. The alterations detected at the 
level of the sensorial component of pain, either soon after the injection and its 
perpetuation over time, are due to alterations on sensorial nerves, which have been 
described by others [66]. 
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Enhanced pain sensitivity is a well-established hallmark of paclitaxel-induced 
neuropathy, but most of the animal studies on this subject have only focused on how and 
to what extent paclitaxel alters the sensorial component of pain. It is also likely that 
paclitaxel treatment impacts on the emotional/affective component of pain since a recent 
finding showed that under administration of a cumulative dose of paclitaxel similar to our 
study, the observed mechanical allodynia was paralleled by increased excitability in the 
anterior cingulate cortex (ACC) [33], which is an area involved in the pain aversiveness 
circuit [30]. To study whether paclitaxel impacts on the emotional/affective dimension of 
pain, we started by detecting whether paclitaxel administration was associated to a 
negative emotion which would be demonstrated by place avoidance or aversion in the 
CPA test. The CPA paradigm was then used under the assumption that if paclitaxel 
induces mechanical allodynia soon after i.p. injection, the animals would promptly 
associate the unpleasantness of the drug to the compartment where they receive the 
drug, which then would motivate avoidance/escaping from this compartment. Our 
preliminary results show that paclitaxel induces place aversion. We also wanted to see 
whether the animals maintained the aversiveness towards the paclitaxel-associated 
compartment, and for that we placed them again in the CPA box one week later. The 
animals’ behavior remained unchanged from the first post-conditioning session and the 
fact that they could still associate that compartment to the unpleasant feeling of receiving 
paclitaxel after one week indicates that paclitaxel induced a strong negative emotion and 
that memory remained intact. The fact that they did not spend a considerable amount of 
time in the saline-paired compartment means that they escaped indiscriminately from the 
paclitaxel-associated compartment to any of the available compartments (both saline-
paired and neutral compartments). We must also say that the vehicle DMSO-treated 
animal also displayed an escape response towards the DMSO-paired compartment. 
Nonetheless, it was only a single animal and we need to increase the number of vehicle-
treated animals as well as the number of paclitaxel-treated animals to validate our initial 
hypothesis.  
 
2. Central sensitization 
 
Along with the changes in nociceptive behavior, functional changes in the 
processing of sensory information by spinal cord neurons have been reported following 
paclitaxel treatment by electrophysiological studies. These studies revealed sensitization 
mechanisms including spontaneous activity in wide-dynamic-range neurons of the spinal 
dorsal horn and increased after-discharges to noxious mechanical stimuli, increased 
neuronal responses to both skin heating and cooling, and windup, which is defined as 
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increased number of discharges in spinal neurons occurring with repetitive 
transcutaneous electrical stimulation of C-fibers [98]. Here we aimed to study whether 
the phenomena of central sensitization could also be monitored by the expression of two 
classical markers of neuronal activation such as pCREB [79] and c-Fos, the latter being 
a specific marker of nociceptive activity at the spinal dorsal horn [99].  
In our study, under basal conditions (i.e., without nociceptive stimulation), there 
were no differences in the spinal expression of pCREB between paclitaxel and DMSO 
treatments. However, saline-treated animals showed a higher expression of the protein 
in comparison to both paclitaxel- and DMSO-treated animals. These results indicate that 
the vehicle DMSO impacts on the expression of pCREB. DMSO alone might be acting 
to reduce spinal neuronal activity as seen by the decreased expression of pCREB. In 
fact, DMSO was shown to block depolarization through inhibition of potassium channels 
on C-fibers at low concentrations [100]. It was also shown to cross the blood-brain barrier 
[101], which would enable an action on spinal dorsal horn neurons and cause inhibition 
of their activity. The DMSO effect, however, did not significantly impact on spinal 
nociceptive activation since the expression of the marker, c-Fos, for spinal nociceptive 
activation was increased after noxious stimulation in paclitaxel-treated animals 
compared to DMSO-treated animals. Our study also revealed that, although we cannot 
assume treatment-dependency, labelling of pCREB protein was more intensely 
observed in the superficial dorsal horn laminae I-II, the spinal laminae receiving noxious 
peripheral input, which is consistent with previous studies on the expression of spinal 
pCREB [102].  
We assessed c-Fos expression as a marker for neuronal activation in the spinal 
cord under noxious stimulation. Under normal conditions, c-Fos expression markedly 
increases in spinal dorsal horn neurons upon noxious stimuli because its protein product, 
FOS, plays a role in the signaling cascade leading to the production of peptides important 
for nociceptive neurotransmission [80, 103, 104]. We used a cold stimulation at 0ºC, 
which induced a higher level of c-Fos expression in the spinal dorsal horn of paclitaxel-
treated animals compared to DMSO-treated animals. The application of noxious cold to 
the hind paws of animals, at temperatures below 0ºC, has been demonstrated to activate 
c-Fos expression in the superficial and deep dorsal horn and the expression of c-Fos 
was shown to be dependent on the intensity and duration of the cold stimulus [12, 99]. 
Abbadie et al. (1994) [99] reported that the threshold to induce c-Fos expression was -
15°C, with little or no expression detected in the lumbar spinal cord when the paws were 
submitted to temperatures between 15 and -10°C. Compared to Abbadie et al. (1994) 
[99], our results indicate that paclitaxel treatment decreases the threshold of c-Fos 
activation, since at 0ºC the expression of this marker is significantly increased in 
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paclitaxel-treated animals. Saline-treated animals were not processed due to previous 
studies indicating that, under normal conditions, 0ºC would not be sufficient to induce c-
Fos activation [12, 99]. We, therefore, did not inflict discomfort to an additional group of 
animals. The DMSO-treated animals showed less c-Fos expression than paclitaxel-
treated animals, but the c-Fos immunoreactivity was higher than expected for these 
animals, probably because the stimulation was prolonged and repeated (3 times for 50 
s each). Regarding the distribution of the FOS protein in the dorsal horn, the highest 
number of c-Fos-IR nuclei was detected in lamina III. This result is surprising and not 
supported by studies on spinal c-Fos expression which have reported it to be mainly 
expressed in laminae I-II and V, which is also the location of spinal neurons that receive 
noxious input from Aδ-fibers and C-fibers, the pain conducting fibers [12, 99, 103]. One 
possible explanation for our result could be that the central terminals of Aδ- and/or C-
fibers sprout into lamina III and activate local spinal neurons. Alternatively, it could be 
due to a switch in the activity of Aβ-fibers, that project to lamina III, which would make 
them also conduct noxious stimuli information as a consequence of paclitaxel action in 
the peripheral sensory nerves. Indeed, Aβ fibers, which normally signal innocuous 
sensations, reportedly begin to produce pain after neural lesions [105]. 
Out of the two markers, only c-Fos effectively revealed increased activation of 
spinal dorsal horn neurons following paclitaxel treatment, which could be indicative of 
central sensitization. It is noteworthy to mention that the increased activity of spinal 
nociceptive neurons we detected is likely peripherally-driven since paclitaxel has a 
limited ability to cross the blood-brain barrier due to the presence of the multidrug 
transporter P-glycoprotein in the endothelial cells of the blood capillaries that make up 
the blood-brain barrier. This transporter blocks the transport of paclitaxel. Indeed, the 
inhibition of this transporter has been shown to promote the entry of paclitaxel to the 
cerebrospinal fluid [106, 107].  
 
3. Engagement of descending noradrenergic modulation 
 
Plastic changes in the descending modulatory pathways are known to occur 
during neuropathic pain in rodent models of neuropathic pain and in humans [108]. It is 
known that these changes result in the disruption of the balance between descending 
modulatory circuits favoring facilitation, concomitantly with diminished descending 
inhibition, both alterations contributing to maintaining chronic pain. The descending 
noradrenergic system exerts inhibitory control of pain by releasing noradrenaline in the 
spinal cord via projections originating from noradrenergic nuclei in the brain (the locus 
coeruleus or A6, A5 and A7 nuclei). Noradrenaline in the spinal cord acts on presynaptic 
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and postsynaptic spinal neurons to inhibit transmission of pain signals [14]. There may 
be a depressed functionality of this system during neuropathic pain since the 
administration of noradrenaline reuptake inhibitors in chronic pain patients ameliorates 
pain [109]. But there is also some evidence suggesting that the activity of the descending 
noradrenergic system may actually be augmented as to compensate the enhanced 
nociceptive input in conditions of nerve injury [108]. In our model of chemotherapy-
induced neuropathy, whether paclitaxel promotes a loss or an engagement of 
descending noradrenergic inhibition is not yet known, but our results point to the second 
hypothesis. Indeed, the expression of DBH, one of the enzymes of the noradrenergic 
biosynthetic pathway, is increased in the spinal L4 segment of paclitaxel-treated animals 
in comparison to DMSO-treated animals at one month after CIN induction. This enzyme 
is primarily synthetized in the cell body of noradrenergic neurons and is then transported 
to neuronal terminals, including the spinal terminals of noradrenergic neurons [20]. The 
increase in the density of DBH-IR positive fibers after paclitaxel treatment is indicative of 
increased DBH expression and possibly an increase of noradrenaline release in the 
spinal cord. It is possible that the increased DBH labelling originates from local sprouting 
of terminals of the descending noradrenergic fibers. This process was shown after nerve 
injury, in a model of chronic constriction injury, where increased density of noradrenergic 
fibers in the spinal cord was associated to increased brain derived nerve growth factor 
(BDNF), a neurothrophin known for its role in differentiation of neurons and plasticity 
processes related to pain [110]. This increase in DBH expression suggests that there 
might be a recruitment of the descending noradrenergic inhibitory system, probably in 
response to a depression of local spinal inhibition. Indeed, recently paclitaxel treatment 
was shown to increase the spinal expression of the gamma-aminobutyric acid (GABA) 
transporter 1 (GAT-1), which consequently reduces ambient GABA levels and decreases 
inhibitory tone [111, 112]. On the other hand, the descending noradrenergic inhibitory 
system may also be recruited in response to increased excitability of spinal nociceptive 
neurons, as the expression of glutamate transporter proteins in the dorsal horn was 
shown to be decreased after paclitaxel treatment, which increased glutamate at the 
synaptic clefts [98]. In our study, increased expression of c-Fos corroborates the thesis 
of increased neuronal activation. These findings suggest that both increased spinal 
excitability and reduced spinal inhibitory tone are contributing to amplify excitatory 
transmission, which may be a signal for the brain to reinforce descending inhibitory 
modulation. For this part of our study, we investigated the influence of time in the 
maintenance of paclitaxel-induced plastic changes in the spinal cord. Our results 
revealed that DBH expression was increased at one month after CIN induction but not 
at two months. Since our animals were still displaying mechanical allodynia at two 
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months, we speculate that the absence of alterations compared to control animals at two 
months was probably due to wear-out of the noradrenergic system resulting from 
continuous input from the periphery. Although we were not able to confirm whether 
increased DBH expression results in increased noradrenaline production and release in 
the spinal cord, previous work showed that increased DBH expression results in 
increased noradrenaline [110, 113].  
Noradrenaline exerts analgesia by acting on spinal presynaptic and postsynaptic 
α2-ARs, which are located on primary afferent terminals and local nociceptive dorsal horn 
neurons, respectively. Decreased expression or activity of these receptors is sometimes 
pointed to contribute to the loss of inhibitory tone in the spinal cord during neuropathic 
pain states [21, 83]. We studied the expression of α2A-ARs in L4 and L5 spinal lumbar 
segments by western blotting and by immunofluorescence. For the western blotting 
analysis, we isolated the entire portion of the dorsal horn while in the 
immunofluorescence study we were able to spatially isolate the superficial dorsal horn 
laminae, which receive the terminal fields of the primary sensory neurons. The western 
blotting study showed no differences in the expression of α2A-Ars within the whole dorsal 
horn of the L4-L5 bulk of paclitaxel- and DMSO-treated animals. The analysis of the 
superficial laminae of L4 and L5 segments, separately, showed that the spinal 
expression of the α2A-AR subtype was also not significantly altered by paclitaxel 
treatment in the superficial laminae of the L4 segment, but it was reduced in the 
superficial laminae of the L5 segment, although only compared to saline-treated animals 
only. Although the reduction of α2A-ARs in the L5 segment was not very strong and was 
only revealed when comparing paclitaxel-treated animals with saline control animals, we 
cannot exclude that paclitaxel treatment might have had a higher impact on the 
peripheral nerves projecting to the L5 segment. Our results suggest that there is not a 
relationship between density of noradrenergic fibers and expression of α2A-ARs, i.e., in 
the spinal L5 segment there is a decreased expression of the receptor but it is not 
accompanied by a significant increase in the density of those fibers. It seems that, even 
though they integrate the same system, their expression is not dependent on one 
another. Whether the expression of this receptor subtype is altered during different 
neuropathic pain states is not consensual among different studies, but a commonly 
reported observation in such studies is that there is an augmented efficacy in the 
antinociceptive activity of the α2A-AR when its agonist clonidine is administered, which 
we confirmed. Our study revealed that, even though the expression of the receptor was 
decreased at some level or remained unchanged, the effects of intrathecally 
administered clonidine were markedly higher in paclitaxel-treated animals as indicated 
by the amelioration of mechanical allodynia and cold hyperalgesia. The effect was 
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greater on mechanical nociception, though. It seems that the dose of 1 µg of clonidine 
was not sufficient to reduce sensitivity to noxious cold but it was sufficient to reduce 
sensitivity to mechanical stimulation. This modality-specific effect is a common feature 
of the noradrenergic system, which seems to be more specifically engaged in the 
inhibition of mechanical nociception [114, 115]. This means that, clonidine may or may 
not exert a dose-dependent effect depending on the nature of the stimulus. We cannot 
completely attribute the increased efficacy of clonidine antinociceptive activity to α2A-AR 
subtype because clonidine has been shown to also bind to the α2C-AR subtype, although 
with much less affinity [21]. We did not determine the expression of the α2C-AR subtype, 
which is also expressed by spinal neurons [20], but it would have been interesting to 
study whether paclitaxel treatment also changes the expression of the α2C-AR subtype 
and how it could contribute to the increased effect of clonidine. The reason for the 
increased potency of the receptor was viewed in other models of neuropathic pain as the 
result of increased efficiency of G protein coupling to α2-AR [116]. It would be interesting 
in the future to further study the involvement of G proteins activation in this model of 
neuropathy. 
 
4. Conclusions and future perspectives 
 
The studies developed during the present thesis helped to unravel alterations at 
the level of the central nervous system, namely in what concerns the descending 
noradrenergic modulatory system. The behavioral studies demonstrated that paclitaxel 
affects both the sensorial and the emotional dimensions of pain. While the development 
of mechanical allodynia is commonly reported in other rat studies, the aversiveness of 
paclitaxel had been, up until now, quite unappreciated. However, to complete our 
preliminary findings with the CPA test, there is a need to complete the study by increasing 
the number of animals and it would also be interesting to understand the mechanisms 
involved in paclitaxel-induced aversion in the brain. The results obtained suggest a 
recruitment of the descending noradrenergic inhibition pathways based on the spinal 
increased noradrenergic innervation and the spinal α2-AR function potentiation in the 
paclitaxel-treated animals. It would be interesting to continue the studies and determine 
whether the increased noradrenergic innervation is paralleled by increased 
noradrenaline release in the spinal cord. For that, it would be interesting to quantify 
noradrenaline using high performance liquid chromatography (HPLC). The potentiation 
of the α2-AR might reflect alterations in the intracellular G-protein coupled receptor 
signaling. It would be interesting to pursue the study to understand the mechanisms 
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engaged in the potentiation of the receptor as it could open new avenues for the 
treatment of neuropathic pain during chemotherapy. 
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Appendix A: Composition of solutions 
 
1. PHOSPHATE BUFFER SALINE (PBS) (1 L) 
 
Phosphate buffer (PB) 0.1 M pH = 7.2: 
Na2H2PO4H2O – 15.60 g 
K2HPO4 – 17.4 g 
H2O up to 1L 
 
PBS: 
PB 250 ml 
H2O up to 1 L 
NaCl – 9 g 
 
2. PHOSPHATE BUFFER SALINE WITH TRITON X-100 (PBS-T) 
 
PBS – 996 ml 
Triton X-100 – 4 ml 
 
3. TYRODE’S SOLUTION (1 L) 
 
NaCl – 6.8 g 
KCl – 0.40 g 
MgCl2.6H2O – 0.32 g 
MgSO4.7H2O – 0.1 g 
NaH2(PO4).H2O – 0.17 g 
Glucose 1 g 
NaHCO3 – 2.2 g 
H2O up to 1 L 
 
4. CRYOPROTECTOR SOLUTION (1 L) 
 
PB 0.1 M pH = 7.2 – 125 ml 
H2O – 375 ml 
Sucrose – 300 g 
Ethylene glycol – 300 ml 
PB 0.1 M pH = 7.2 up to 1 L 
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Appendix B: Publication and oral communication 
 
1. Abstract publication on “Porto Biomedical Journal” entitled “Paclitaxel-induced 
neuropathic pain: Unravelling the underlying mechanisms at the central nervous 
system”. 
 
2. Oral presentation in the Plenary session (“Neurosciences” field) at the 12th Young 
European Scientist Meeting (14th September-17th September 2017), at Faculty of 
Medicine of the University of Porto. 
